Outcome measures	B	3 m	6 m	9 m	12 m	R

Questionnaires

Patient

CCQ	X

MRC dyspnea	X

SGRQ	X	X	X	X	X

McGill QOL	X	X	X	X	X

HADS	X	X	X	X	X

Illness understanding	X	X	X	X	X

Demographic questionnaire	X

Informal caregiver

SPPIC	X	X	X	X	X

HADS	X	X	X	X	X

Illness understanding	X	X	X	X	X

Demographic questionnaire	X

Lung specialist

CRF	X

Medical files

Number of hospitalisations of unexpected hospital admissions for AECOPD	 	 	 	 	 	X

Number of days of unexpected hospital admissions for AECOPD	 	 	 	 	 	X

Number of hospitalisations of unexpected ICU admissions for AECOPD	 	 	 	 	 	X

Number of days of unexpected ICU admissions for AECOPD	 	 	 	 	 	X

Are the choices of ACP documented in the medical file at baseline? (when yes/when no)	 	 	 	 	 	X

Are the choices of ACP documented in the medical file after one year or at time of death? (when yes/when no)	 	 	 	 	 	X

Did the patient die within one year after inclusion? (when yes/when no)	 	 	 	 	 	X

Date of death	 	 	 	 	 	X

Place of death (ICU/hospital/hospice/nursing home/at home)	 	 	 	 	 	X

Is preferred place of death known? (when yes/when no)	 	 	 	 	 	X

Has this wish come true? (when yes/when no)	 	 	 	 	 	X

Primary cause of death (pulmonary insufficiency/other cause)	 	 	 	 	 	X

Secondary cause of death (pulmonary insufficiency/other cause)	 	 	 	 	 	X

Did the patient have an unexpected hospital readmission for AECOPD within 8 weeks? (when yes/when no)	 	 	 	 	 	X

Date of first unexpected hospital readmission for AECOPD.	 	 	 	 	 	X


 	Botanical name	Family	Common name	Density (ind/hectare) mean ± stdv	Uses

1	Virola surinamensis (Rol.) Warb.	Myristicaceae	Urucurana	97.3 ± 97.1	M, T, O

2	Xylopia brasiliensis Sprengel	Annonaceae	Pindaíba	63.3 ± 60.3	-

3	Carapa guianesenis Aubl.	Meliaceae	Andiroba	46.7 ± 50.3	M, T, O

4	Symphonia globulifera Linn. f.	Clusiaceae	Guanandi/Guananim	43.4 ± 40.4	M, T

5	Mauritia flexuosa L.F.	Arecaceae	Buriti	33.3 ± 32.1	F, S

6	Euterpe oleraceae Mart.	Arecaceae	Juçara/Açai	33.3 ± 43.6	F, H

7	Richeria dressleri G.L. Webster	Phyllanthaceae	Jaca-da-baixa	30.0 ± 43.6	-

8	Anacardium sp.	Anacardiaceae	Caju-da-baixa	26.7 ± 46.2	F

9	n.i.	n.i.	Casca-grossa	20.0 ± 34.6	-

10	Attalea maripa (Aubl.) Mart	Arecaceae	Inajá	16.7 ± 15.3	F, H, O

11	Tapirira guianensis Aubl.	Anacardiaceae	Pau-pombo	16.7 ± 15.3	-

12	Annona sp	Annonaceae	Araticum-da-baixa	13.3 ± 5.8	F


Polymorphism	Strand	Primer sequence

rs429358 (APOE)	Sense	5′-GAACTGGAGGAACAACTGAC

Antisense	5′-CGCTCGCGGATGGCGCTGA

rs7412 (APOE)	Sense	5′-GAACTGGAGGAACAACTGAC

Antisense	5′-CGCTCGCGGATGGCGCTGA

rs4680 (COMT)	Sense	5′-GCTACTCAGCTGTGCGCATG

Antisense	5′-ACGTGGTGTGAACACCTGGT

SL6A3 repeat (DAT1)	Sense	5′-TGTGTGCGTGCATGTGG

Antisense	5′-GCTTGGGGAAGGAAGGG

rs1108580 (DBH)	Sense	5′-ACGCCTGGAGTGACCAGAAG

Antisense	5′-CCATCCTCCTTGGCTTTCTC

rs747302 (DRD4)	Sense	5′-CGGAGGGAATGGAGGAGGGA

Antisense	5′-AGACCTGAGCTCAGGCTCTG


Variable	OR	95% CI

Age

 17–24	1.2	0.49, 3.1

 25–34	1.0

 35 and over	0.84	0.29, 2.4

First Pregnancy

 No	1.0

 Yes	0.75	0.29, 1.9

Highest Level of Education Completed

 Less than Secondary School	1.0

 Secondary School or Beyond	3.4*	1.6, 7.3

Number of Durable Goods Owned

 0	1.0

 1–2	2.2	0.60, 7.8

 3–4	3.1	0.80, 11

Employment Status

 Never had a job	1.0

 Currently unemployed	1.1	0.41, 2.8

 Currently employed	0.62	0.28, 1.4

Living with Partner

 No	1.0

 Yes	0.70	0.26, 1.9

Marital Status

 Single	1.0

 Married	2.5	0.74, 8.8

Believe mosquito nets that you have to buy are better quality (more effective in preventing malaria) than nets that are given out for free

 No	1.0

 Yes	0.36*	0.15, 0.88

Believe children suffer from malaria more than adults

 No	1.0

 Yes	0.49	0.22, 1.1

Think mosquito nets are difficult to use

 No	1.0

 Yes	0.19	0.034, 1.0


	Baseline	6 months after RDN	p value

Office systolic blood pressure (mmHg)	180.4 ± 6.79	164.8 ± 8.06	0.01

Office diastolic blood pressure (mmHg)	94.88 ± 4.72	87.88 ± 3.63	0.04

Daytime ABPM systolic (mmHg)	158.3 ± 4.72	154.4 ± 5.53	0.49

Daytime ABPM diastolic (mmHg)	89.43 ± 2.84	88.29 ± 4.32	0.74

Nighttime ABPM systolic (mmHg)	151.3 ± 5.78	138.1 ± 8.00	0.06

Nighttime ABPM diastolic (mmHg)	83.71 ± 2.80	75.57 ± 4.64	0.03


Primer	Sequence (5′-3′)

F3	CTCGTGTCGTGAGATGTTG

B3	GAACGTATTCACCGTGGC

FIP	CCCACTCCATAAGGGCCATGAGGGACTTTAAGGAAACTGCC

BIP	CAATGGTGGCTACAATGGGCTGGCAGAGTACAATCCGAACTG

LoopF	CCACCTTCCTCCAGTTTATCAC

LoopB	CGCGAGGCTAAGCTAATCC


	Original CE scale	New CE scale	New CE scale—social cohesion subscale	New CE scale— informal social control subscale

Disorder	−0.39	−0.33	−0.28	−0.33

Exchange	0.43	0.53	0.52	0.41


Research question	Outcome	Method of analysis	Results from the model data set

All respondents, n = 244	Highly compliant respondents, answering 80% (≥15/18 weeks), n = 161

4A: Association of baseline variables with outcome	Weekly recorded pain days, count variable, assuming a binominal distribution	Multilevel mixed-effects logistic regression or generalized estimating equation assuming a logit link function (Long previous duration reference category)	Subject specific OR = 3.31 (95% CI: 2.1-5.1) Population average OR = 1.96 (95% CI 1.4-2.6) (Note: Interaction duration*week significant)	Subject specific OR = 2.67 (95% CI: 1.6-4.5) Population average OR =1.52 (95% CI 1.1- 2.2) (Note: Interaction duration*week significant)

4B: Association of baseline variables with outcome	Weekly recorded pain days, count variable, assuming a Poisson distribution	Multilevel mixed-effects Poisson regression assuming a log link function (Long previous duration reference category)	Subject specific IRR = 1.92 (95% CI: 1.5 – 2.4) (Note: Interaction duration*week significant)	Subject specific IRR = 1.82 (95% CI: 1.4 – 2.4) (Note: Interaction duration*week significant)

4 C: Association of baseline variables with outcome	Weekly recorded pain days, considered a count variable and assuming a normal distribution	Generalized linear regression or mixed linear model assuming an identity link function	Average difference in pain days for Long duration – Short duration 1.20 (95% CI: 0.8 – 1.5) (Note: Interaction duration*week significant)	Average difference in pain days for Long duration –Short duration 0.95 (95% CI: 0.6-1.4) Note: Interaction duration*week significant)


Antibody	Species	Epitope	Dilution

Santa Cruz #sc-1751	Goat polyclonal (clone C-20)	near C-terminus	1:300

Santa Cruz #sc-48371	Mouse monoclonal (clone D-9)	aa 21-140 (near N-terminus)	1:200

Santa Cruz #sc-28237	Rabbit polyclonal (clone H-120)	aa 21-140 (near N-terminus)	1:300

Abcam #ab140595	Rabbit monoclonal	aa 350 to the C-terminus	1:100

Abcam #ab40693	Rabbit polyclonal	aa 350 to the C-terminus	1:500

ProteinTech #12133-2-AP	Rabbit polyclonal	human TIA1-GST fusion protein	1:100


Response*	Percent (n = 83)

I managed the patient myself	34

The patient improved while waiting to be seen	29

I referred to a pediatric infectious disease specialist instead	28

I referred to adult rheumatologist instead	20

I referred to a pediatric orthopedist instead	12

I referred to a pediatric hematology/oncology specialist instead	9

Other	9

The distance or time to travel was too long	8

I referred to a pediatric sports medicine specialist instead	4

I referred to a general orthopedist instead	4

The patient’s insurance would not cover a PR referral	1


	HC 1 (%)	HC 2 (%)

Frequency of product consumption

More than once per day	42	46

Once per day	58	54

Amount of product given per day

<1 sachet	18	4

1 sachet	80	96

>1 sachet	2	0

Child took product as instructed

Yes, always or most of time	83	85

Yes, about half the time	7	0

No, usually not	11	8

No response	1	2


Variables	Subgroup	N	Mean rank	Sum rank	U	p

Lymphovascular invasion	No	85	69.88	5939.50	1285.500	0.010

	Yes	42	52.11	2188.50

PIK3CA gene mutation	Wild type	120	62.23	7467.00	207.000	0.024

	Mutation	7	94.43	661.00


Diagnosis	No.	M:F ratio	Median age (Range)	Diagnostic category	Blind in at least one eye (%)	Previously diagnosed (%)

				1	2	3

POAG with normal IOP	50	26:24	63 (53–99)	36	14	0	4 (8)	2 (4)

POAG with high IOP	22	11:11	66 (51–86)	13	5	4	5 (22.73)	6 (27.27)

Total POAG	72	37:35	65 (51–99)	49	19	4	9 (12.5)	8 (11.11)


Group	Thickness	Buckling value, μm

ds, μm	db, μm	Experiment	Model

2	42	83	1.55	1.59

3	42	97	1.31	1.42

4	31	83	0.90	1.03


Cells	Stimulus	Effect	Reference

Alveolar macrophages	LPS	↓ inflammatory cytokines	Baldwin et al. [16]

 	Pacifici et al. [17]

Monocytes	LPS	↓ inflammatory cytokines	Zurier et al. [95]

Impairs differentiation to dendritic cells	Roth et al. [122]

Thioglycollate-elicited macrophages	 LPS	↓ tumor necrosis factor-α protein processing	 Zheng and Specter [99]

↑ interleukin-1β	Zhu et al. [94]

LPS/interferon-γ	↓ nitric oxide synthase-2	Coffey et al. [102]

↓ nitric oxide	Mestre et al. [92]

↑ interleukin-10	Correa et al. [109]

Blood mononuclear cells	LPS	↓ interleukin-1α	Watzl et al. [96]

Biphasic dose-response	Berdyshev et al. [97]

Microglial cells	LPS	↓ cytokine mRNA	Puffenbarger et al. [103]

↑ IL-1 receptor antagonist	Molina-Holgado et al. [111]

↓ nitric oxide	Merighi et al. [123]

LPS/interferon-γ	↑ interleukin-10	Correa et al. [110]

↓ nitric oxide	Waksman et al. [124]

Dendritic cells	LPS	↓ TLR4 expression	Xu et al. [106]

BV-2 cells	LPS	↓ NF-κB activity	More et al. [101]

↓ cytokine mRNA

↓ interferon-β mRNA	Kozela et al. [125]

J774 cells	LPS	↓ nitric oxide	Chang et al. [93]

↓ interleukin-6

↓ cyclooxygenase-2

RAW 264.7 cells	LPS	↓ tumor necrosis factor-α protein processing	Fischer-Stenger et al. [100]

↓ nitric oxide synthase-2	Jeon et al. [104]

↓ nitric oxide

↓ NF-κB activity

TLR4-transfected HEK293 cells	LPS	↓ interferon-β mRNA	Downer et al. [126]

↓ IRF3 activity

Glioma U87MG cells	Peptidoglycan	↓ NF-κB activity	Echigo et al. [105]

TLR3-transfected HEK293 cells	Polyinosinic:polycytidylic acid	↑ interferon-β mRNA	Downer et al. [127]

↑ IRF3 activity	Downer et al. [126]

↓ tumor necrosis factor-α

↓ NF-κB activity

Blood mononuclear cells	Polyinosinic:polycytidylic acid	↑ interferon-β mRNA	Downer et al. [126]

↓ tumor necrosis factor-α


 	N, n	Mean performance score	SD	F-test, p-value

Location	67	-	-	0.028*

 National government hospital 1	16	32.6	11.0

 Regional government hospital 2	17	22.5	8.1

 Regional government hospital 3	15	27.4	10.6

 District government hospital 4	12	26.8	9.6

 District private non-profit hospital 5	7	21.3	6.1

Type of near-miss complication	67	-	-	0.7*

 NM haemorrhage	28	27.0	11.8

 NM hypertensive disorder	17	25.9	9.9

 NM obstructed labour	13	28.1	9.2

 NM infection/sepsis	6	27.7	5.6

 NM anaemia	3	18.8	4.4

Project maturity	67	-	-	0.5*

 First half of audits	33	27.5	10.2

 Second half of audits	34	25.9	10.1

Moderation of audit team	50#	-	-	0.030*

 by a midwife	24	23.4	9.1

 by a physician	26	29.7	10.7


Use categories	No. of taxa	No. of use reports	Consensus factor

Stomach disorder (diarrhoea/dysentry)	8	178	0.96

Cuts and wounds	4	160	0.98

Fever and headache	6	125	0.96

Skin diseases/skin irritation	2	4	0.67

Worms in stomach	2	120	0.99

Nausea and vomiting	2	73	0.98

Snake and scorpion bites	2	8	0.85

Cough and cold	4	186	0.98


Category	Males	Females	Total

People living with HIV	9	14	23

 Intervention	5	10	15

 Control	4	4	8

Peer Supporters	3	6	9

Program staff	3	4	7

Total	15	24	39


	Overall (%)	Non-Hispanic White (%)	Non-Hispanic Black (%)	Hispanic (%)	Other (%)

N	1005	649	118	157	81

During past 12 months, have you received a flu shot or vaccine?

 Yes	42.3	45.4 a	50.9 a	20.8 b	44.4 a

 No	57.7	54.6 a	49.1 a	79.2 b	55.6 a

If yes, in which month did you receive your most recent flu vaccine?

 September	27.7	27.6	33.3	27.6	20.0

 October	40.8	43.8	33.3	27.6	40.0

 November	18.2	16.9	14.8	27.6	28.6

 December	2.6	3.4	1.9	0.0	0.0

 January/February	4.3	3.1 a	5.6 a	13.8 b	5.8 a

How likely are you to get a flu Vaccination this season (2016–2017)—that is, this Fall or Winter?

 Already received	13.5	14.7 a,b	19.3 b	6.5 c	8.8 a,c

 Will definitely get one	26.7	27.6 a	31.1 a	18.2 b	27.5 a,b

 Will probably get one	13.8	12.0 a	10.1 a	18.8 b	25.0 b

 Will probably not get one	18.9	20.8 a	15.1 a,b	19.5 a	8.8 b

 Will definitely not get one	27.0	24.8 a	24.4 a	37.0 b	30.0 a,b

Thinking about 2013, 2014, and 2015, in how many of those years did you get a flu vaccination?

 Received in all three years	35.7	39.7 a	37.9 a	16.4 b	33.8 a

 Received in two years	10.7	9.5	13.8	12.9	12.5

 Received one year	12.5	11.0 a	12.1 a,b	19.3 b	15.0 a,b

 None	41.1	39.7 a	36.2 a	51.4 b	38.8 a,b

Have you ever delayed getting a recommended flu vaccination for reasons other than illness or allergy?

 Yes	19.2	19.8	19.5	17.2	17.3

Have you ever declined getting a recommended flu vaccination for reasons other than illness or allergy?

 Yes	29.5	31.9 a	18.6 b	27.8 a,b	29.6 a,b


Name 	Amount [mg/100g Star-fruit weight]*

Carotene	0.003 - 0.55

Tartaric acid	4.37

Oxalic acid	9.6

Ketoglutaric acid	2.2

Citric acid	1.32

Vitamin B1 & B2	0.12

Vitamin C	25.8

*on a dry weight basis


Serial no.	Class of Motifs	No. of exclusive IFN-γ peptide	No. of exclusive rest of cytokine inducing peptide

1	None	696	384

2	Koolman-Rohm	1481	219

3	Betts-Russell (Hydorphobic)	1731	187

4	Betts-Russell (Polar)	1318	234

5	Betts-Russell (Small)	1668	186

6	ALL class	3058	679


	22q11DSMean (SD)	Median	HCMean (SD)	Median	Statistic (p), effect size (r)

BORB

 Field dependence/independence

Figure-ground segmentation

Single letters	0.90 (0.1)	0.92	0.84 (0.1)	0.84	0.04 (0.23) NS

Paired drawings	0.97 (0.2)	0.97	0.88 (0.1)	0.89	0.40 (0.08) NS

Triplet letters	0.96 (0.1)	0.95	0.95 (0.2)	0.88	0.03 (0.23) NS

 Form perception

Form perception easy sub-tests (easy foreshortened + easy minimal features)	47.20 (2.78)	48.0	49.13 (1.38)	50.0	0.001 (0.43)

Form perception hard sub-tests (hard foreshortened + hard minimal features)	38.91 (4.1)	40.0	41.76 (1.8)	43.0	0.001 (0.43)

 Visual object recognition

Picture naming	12.56 (1.87)	13.0	13.70 (1.66)	14.0	0.001 (0.37)

 Implicit memory

Object decision (easy)	28.04 (3.94)		29.83 (1.49)

Object decision (hard)	24.7 0(3.48)		26.53 (3.03)

 Implicit memory sub-total	53.04 (5.88)	54.0	56.37 (3.36)	57.0	0.003 (0.33)

 Semantic memory

Associative matching	27.29 (3.07)	28.0	29.27 (1.08)	30.0	0.001 (0.44)

 Embedded figures test

Total score	21.10 (4.0)	22.0	22.22 (1.85)	23.0	0.5 (0.09) NS

Reaction time (s)	33.89 (17.1)	30.3	26.76 (12.06)	24.3	0.07 (0.22) NS


Receptor	t1/2

LRP	0.5 min

LDLR	4.8 min

ApoER2	8.1 min

VLDLR	8.2 min


Index/subtests/development scales	WPPSI-III

N 	IQ/DQ/scores	Subtest mean	Std. deviation	Range

WPPSI verbal IQ (VIQ)	113	84,8	 	16,1	53–133

Information	112	 	7,4	3,3	1–16

Vocabulary	110	 	7,4	2,9	2–16

Word Reasoning	111	 	7,2	3,1	1–15

Comprehension	63	 	9,0	2,9	3–15

Similarities	67	 	7,9	2,6	3–15

WPPSI performance IQ (PIQ)	113	93,6	 	16,7	53–135

Block Design	112	 	10,3	3,6	1–18

Matrix Reasoning	111	 	8,8	3,5	1–16

Picture Concepts	111	 	8,2	3,4	1–17

Picture Completion	67	 	9,6	3,5	2–19

WPPSI Processing speed (PSQ)	85	76,7	 	12,2	49–107

Coding	110	 	5,1	2,9	1–12

Symbol Search	95	 	5,9	2,6	2–14

WPPSI General Language (GLC)	99	89,9	 	17,1	45–128

Receptive Vocabulary	96	 	8,2	3,1	1–15

Picture Naming	95	 	8,5	3,2	2–16

WPPSI full scale IQ (FSIQ)	113	84,5	 	14,7	51–121

Griffiths' verbal functioning	77	33,5	 	15,9	8–72

Griffiths' performance functioning	77	46,7	 	16,3	15–79

Griffiths' global functioning	77	41,6	 	14,5	13–73

VABS Communication	187	71,9	 	18,9	34–120

VABS DLS	187	73,8	 	16,4	38–117

VABS Socialization	187	70,6	 	14,7	46–112

VABS Motor	187	76,4	 	14,5	43–117

VABS total	187	70,5	 	15,0	42–114


Variable

Stroke severity on admission, n (%)

NIHSS 0–5	36 (27.5)

NIHSS 6–10	46 (35.1)

NIHSS 11–16	29 (22.1)

NIHSS >16	17 (13.0)

Undetermined	3 (2.3)

Stroke etiology (TOAST), n (%)

Large artery atherosclerosis	49 (37.4)

Small vessel occlusion	13 (9.9)

Cardioembolic	27 (20.6)

Other/undetermined	42 (32.1)

Imaging data

ASPECTS, median (IQR)

 On admission	10 (9–10)

 24 h after thrombolysis	9 (5–10)

Affected vessel territory, n (%)

 MCA	82 (62.6)

 ICA	11 (8.4)

 MCA + ICA	10 (7.6)

 VB	28 (21.4)

Level of occlusion, n (%)

 No stenosis/occlusion	34 (26.0)

 Stenosis	27 (20.6)

 Occlusion	70 (53.4)

Outcomes, n (%)

Functional outcome at 7 days

 Favorable outcome	49 (37.4)

 No change	42 (32.1)

 Unfavorable outcome	20 (15.3)

Functional outcome at 90 days

 mRS 0–2	57 (43.5)

 mRS 3–6	51 (38.9)

 Undetermined	23 (17.6)

Intracranial hemorrhage (ECASS II)

 aSICH	7 (5.3)

 SICH	6 (4.6)


Variables	Instruments	Time of Measurement

		Baseline/1 week after discharge ICU	6 months	12 months

Pain (intensity, frequency)	NRS	Q	Q	Q

Anxiety (intensity, frequency)	NRS, HADS-D	Q	Q	Q

Agitation (intensity, frequency)	CAM	Q	Q	Q

Mortality	Survival: Yes/No	Q	Q	Q

Morbidity	International classification of diseases, version 10	MR/Q	MR/Q	MR/Q

Quality of life (HR-QOL)1	SF-36	Q	Q	Q


	Baseline	Intervention	Difference	p-value a

Simple reactiontime test

Mean Tput b score (SE)	209 (6)	220 (6)	11 (4)	0.01

Mean reaction time in msec (SE)	293 (9)	279 (9)	-15 (7)	0.03

Complex reactiontime test

Mean Tput b score (SE)	85 (3)	92 (4)	7 (2)	< 0.001

Mean reaction time in msec (SE)	629 (18)	606 (21)	-23 (8)	0.002

Mean % correct (SE)	97.5 (0.4)	98.2 (0.3)	0.7 (0.3)	0.01

Mean lapses c (SE)	5.5 (0.9)	4.3 (1.0)	-1.2 (0.6)	0.05

Mean impulses d (SE)	6.1 (0.8)	4.5 (0.9)	-1.6 (0.4)	< 0.001


Platform	Cost (US$)

Vinoculer	5 K

UAV	16–80 K


Author	Sample size	Prevalence (%)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)

Gaspari et al. [39]	104	51	87	82	84	86

Watkins et al. [40]	57	68	80	83	91	65

Moak et al. [41]	107	36	76	78	66	86

Herbst et al. [42]	670	47	73	73	71	75


Regression parameter	Slope (a)	Intercept (b)	Data point count	R2

value	1.09	0.03	679	0.98


Matrix	Filler	Code name

PP-SL262MW	–	PP

PP-SL262MW	Sol-gel (catalyst: acetic acid)	PP-Acetic

PP-SL262MW	Sol-gel (catalyst: formic acid)	PP-Formic

PP-SL262MW	Sol-gel (catalyst: ammonium hydroxide)	PP-Base

PP-SL262MW	Natural HNT	PP-HNT

PP-SL262MW	Functionalized HNT	PP-PolyHNT

PP-SL262MW	Untreated CNT	PP-CNT

PP-SL262MW	Functionalized CNT	PP-CNTF


Factors	Domain	Data collected	Sources of information

Technical factors	Reporting system	Type of new tools introduced by the NTCP and their use	Interviews

Availability of tuberculosis and routine information tools	Observation

 	Designer of reporting forms	Designer of the routine information system	Interviews

Changes in the design of routine information after TDTC creation

 	Complexity of the reporting forms	Complexity of the tuberculosis and routine information tools	Interviews

 	Procedures	Rules for tuberculosis and routine data collection,analysis and transmission	Document review

Changes in routine HIS procedures following the creation of the TDTC	Interviews

Organisational factors	Information distribution	Type of reports sent by the hospital before and after the creation of the TDTC	Interviews

Services receiving hospital reports

 	Interest devoted to reporting	Motivation of the TDTC staff for reporting	Interviews

Motivation of the ward staff members for reporting

 	Quarterly HIS supervision	Staff members supervised in the use of thetuberculosis HIS (frequency)	Interviews Observation

Staff members supervised in the use of the routine HIS (frequency)

 	Training	Training received on HIS management: trainees and date	Interviews

Behavioural factors	Level of knowledge of content of HIS forms	Staff members involved in monthly routine reporting	Interviews

Knowledge of the content of HIS tools by hospital staff

 	Skills	Skills in data collection, processing and analysis	Interviews

 	Motivation	Level of motivation	Interviews

Processes	Data collection	Data completeness in registers (tuberculosis and routine care data)	Observation

 	Data processing	Availability of tuberculosis and routine reports(period) at the hospital level	Observation

 	Data analysis	Type of analysis conducted on tuberculosis data and on routine data	Interviews Document review

 	Data transmission	Availability of tuberculosis and routine reports (period)at the district and regional levels	Interviews Observation

 	Data display andfeedback to nurses	Type of data displayed (for tuberculosis and routine care data)	Observation

 	Data quality checking	Procedures of data checking and actors involved	Interviews


Variables	Average	Minimum	Maximum

Herd size	100	40	220

Milk production (kg/herd/year)	815,429	340,000	1,850,000

Milk production (kg/cow/year)	8,174	5,333	10,434

Number of present young stock per year	69	19	152


Parameter	% found

Tb+3	La+3	Ce+3

Alkaline degradation FMT added = 20ng/ml

<overline>X</overline>±SD	100.68 ± 0.87	100.18 ± 0.59	100.10 ± 0.58

Student’s t test	0.17 (2.78)	0.53 (2.78)	0.72 (2.78)

Variance ratio F test	1.97 (6.94)	1.10 (6.94)	1.14 (6.94)

Alkaline degradation FMT added= 40ng/ml

<overline>X</overline>±SD	100.08 ± 0.84	99.99 ± 0.50	100.15 ± 0.46

Student’s t test	0.84 (2.78)	0.98 (2.78)	0.50 (2.78)

Variance ratio F test	1.84 (6.94)	1.54 (6.94)	1.82 (6.94)

Oxidative degradation FMT added = 20ng/ml

<overline>X</overline>±SD	99.87 ± 0.71	100.88 ± 0.80	99.90 ± 0.67

Student’s t test	0.70 (2.78)	0.07 (2.78)	0.76 (2.78)

Variance ratio F test	1.31 (6.94)	1.66 (6.94)	1.17 (6.94)

Oxidative degradation FMT added = 40ng/ml

<overline>X</overline>±SD	99.82 ± 0.48	99.89 ± 0.52	100.08 ± 0.73

Student’s t test	0.45 (2.78)	0.66 (2.78)	0.82 (2.78)

Variance ratio F test	1.67 (6.94)	1.42 (6.94)	1.39 (6.94)

Intra-day precision (spiked plasma)

<overline>X</overline>±SD	100.28 ± 2.09	99.67 ±1.28	101.24 ± 1.50

Inter-day precision (spiked plasma)

<overline>X</overline>±SD	100.39 ± 1.59	99.44 ± 1.73	100.30 ± 0.87

Intra-day precision (real plasma)

<overline>X</overline>±SD	97.01 ± 0.75	103.21 ± 0.65	102.13 ± 0.74


	J Inertia (Kg/m2)	R Resister (Ohm)	Kt Torque constant (Nm/A)	Km Restoring constant (Nm/rad)

Simulation	Experiment	Simulation	Experiment

X-axis	3.58e-9	42	4.84e-4	6.25e-4	4.34e-4	4.62e-4

Y-axis	55.65e-9	145	2.14e-2	2.17e-2	7.07e-3	6.28e-3


Characteristics	Feminized Male CRC (Total = 26) No. (%)	Non-Feminized Male CRC (Total = 31) No. (%)	Total Males (Total = 57) No. (%)	p-Value

MSS—wild type BRAF	24 (92.3)	17 (56.7)	41 (72.0)	0.0026 *

Wild-type BRAF	26 (100)	23 (74.2)	49 (86.0)	0.0088 *

MMR proficient	24 (92.3)	19 (61.2)	43 (75.4)	0.0107 *


						Prior Probability of Mutation in a BRCA gene

Case #	Cancer diagnosis (index-case)	Age at diagnosis (ys)	Cancer family history*	ASCO criteria	Limited Family Structure	Myriad Prevalence Tables (%)	Couch Prediction Model (%)

1-RJ	Breast	33	MAT Br (F-45)	Yes	No	16.3	20.0

2-RJ	Ovarian	47	PAT Ov (60), Br (F-30), End (64)	Yes	No	46.8	44.0

3-RS	Ovarian	52	MAT Br (F-44), Ov (F-76), Ov (F-66), Ut (F-78), Ut (N/A), Ga (M-68),CRC (M-69), HeN (M-N/A), HeN (M-75)	No	No	46.8	43.0

			PAT Lu (M-N/A), CRC (M-N/A), CRC (F-N/A), Ut (35), Br (M-62), Ga (M-N/A), Br (F-36), Bilat Br (F-45), Br (F-44), Br (F-45)	Yes	No	40.8	33.0

4-RJ	Bilateral Breast	45 and 50	MAT BilatBr (F-45,50), Ov (39) Br (F-49), Bilat Br (F-47,50)	Yes	No	40.7	31.0

5-RJ	Bilateral Breast	46 and 47	PAT Lu (M-N/A), Ga (M-N/A) CRC (M-N/A)	No	Yes	6.9	9.0

6-RJ	Bilateral Breast	33 and 38	-	No	Yes	6.9	15.0

7-RS	Bilateral Breast	35 and 45	MAT Ov (F-58), Ov (F-49), Br (F-90) Br (F-49), Ga (M-70), Liv (M-70)	Yes	No	40.7	47.0


Oligo ID	Gene	Purpose	Sequences (5' to 3')

swcM1	M	capture	CTGACTAAGGGAATTTTAGGATTTGTGTTCACGCTCACCG

swcM2	M	capture	TGATTCACAGCATCGGTCTCACAGACAGATGGCTACTACC

swcM3	M	capture	AAGGCTATGGAACAGATGGCTGGATCGAGTGAACAGGCAG

swcH1	HA	capture	GAAGGCAATACTAGTAGTTCTGCTATATACATTTGCAACC

swcH2	HA	capture	CCTGGGAAATCCAGAGTGTGAATCACTCTCCACAGCAAGC

swcH3	HA	capture	GTTTTTGTGGGGTCATCAAGATACAGCAAGAAGTTCAAGC

swcH4	HA	capture	GAAGCAAAATTAAACAGAGAAGAAATAGATGGGGTAAAGC

swcN1	NA	capture	TTCGGTCTGTATGACAATTGGAATGGCTAACTTAATATTA

swcN2	NA	capture	GTGGTTTCCGTGAAATTAGCGGGCAATTCCTCTCTCTGCC

swcN3	NA	capture	CAATGGAACCATTAAAGACAGGAGCCCATATCGAACCCTA

swcN4	NA	capture	ACGCCCTAATGATAAGACAGGCAGTTGTGGTCCAGTATCG

swiM1	M	intermediate	AAAGCCGAGATCGCGCAGAGACTGGAAAGTGTCTTTGCAG *

swiM2	M	intermediate	CCACTAATCAGGCATGAAAACAGAATGGTGCTGGCTAGCA *

swiM3	M	intermediate	GCCTGAGTCCATGAGGGAAGAATATCAACAGGAACAGCAG *

swiM4	M	intermediate	AATGGGAGTGCAGATGCAGCGATTCAAGTGATCCTCTCGT *

swiH1	HA	intermediate	AAGACAAGCATAACGGGAAACTATGCAAACTAAGAGGGGT *

swiH2	HA	intermediate	GTGGAAACACCTAGTTCAGACAATGGAACGTGTTACCCAG *

swiH3	HA	intermediate	AAACGGCTGCTTTGAATTTTACCACAAATGCGATAACACG *

swiN1	NA	intermediate	CTTGGGAATCAAAATCAGATTGAAACATGCAATCAAAGCG *

swiN2	NA	intermediate	GTAAAGACAACAGTGTAAGAATCGGTTCCAAGGGGGATGT*

swiN3	NA	intermediate	CAGTCGCTTGGTCAGCAAGTGCTTGTCATGATGGCATCAA *

swiN4	NA	intermediate	TACGGCAATGGTGTTTGGATAGGGAGAACTAAAAGCATTA *

ABI04mF	M	PCR	TAACCGAGGTCGAAACGTA

ABI04mR	M	PCR	TTACTCTAGCTCTATGTTGACAAA

ABI05hF	HA	PCR	ATGAAGGCAATACTAGTAGTTCTGCT

ABI05hR	HA	PCR	TTCTACACTGTAGAGACCCATTAG

ABI06nF	NA	PCR	ATGAATCCAAACCAAAAGATAATAA

ABI06nR	NA	PCR	TTACTTGTCAATGGTAAATGGCAACT


Clinical guidelines directly related to the practice of dentistry	No.

American Dental Association	2

American Academy of Pediatric Dentistry	22

American Cleft Palate Craniofacial Association	1

American Academy of Pediatrics	1

American Academy of Sleep Apnea	1

Center for Disease Control	1

US Preventive Services Task Force	2

New York State Department of Health	2

Health Partners	4

University of Texas at Austin	1

Non US Government Agencies	8

Areas covered by other stomatognathic clinical guidelines

Preventive Services	12

Cancer	3

Infectious Diseases	7

TOTAL	67


Age group	Outcome	Indicator	Measurement tool

Adults	Healthy eating*	Binary: consumption of five or more portions of fruit and vegetables per day (‘five-a-day’)	Food frequency questionnaire

Adults	Healthy physical activity*	Binary: doing five or more sessions of moderate intensity physical activity per week lasting at least 30 min (‘five-a-week’)	International Physical Activity Questionnaire

Adults	Mental wellbeing - positive	Continuous: Hope Scale score	Hope Scale

Adults	Mental wellbeing - negative	Binary: reports feeling anxious or depressed	EQ5D (1 item)

Adults	Mental wellbeing - negative	Binary: reports visiting GP for anxiety or depression or other emotional problem	Individual questionnaire item

Adolescents	Healthy eating - positive	Binary: frequent consumption of fruit	Individual questionnaire item

Adolescents	Healthy eating negative	Continuous: score summarizing frequency of consumption of chips, sweets or chocolate, and s ugar sweetened soft drinksb	Individual questionnaire items

Adolescents	Healthy physical activity*	Continuous: IPAQ score	Physical Activity Questionnaire for Adolescents

Adolescents	Mental health - negative*	Binary: score above threshold for normal mental health	Strengths and Difficulties Questionnaire

Adolescents	Mental health - positive wellbeing*	Continuous: positive affect score and negative affect score	Positive and negative affect scale


		Pre Meeting	Meeting	Test

Gender	Males	27	24	NS

	Females	7	9

Age	(av +/- sd)	46.6 +/- 8.6	44.5 +/- 9.3	NS

Experience	(av +/- sd)	18.3 +/- 10.6	18.3 +/- 10.3	NS

Braces/y	(med – 95% IC)	150 (30–965)	200 (28–1725)	NS

	Less than 100	8	5

	100–300	15	12

	Over 300	5	9

Profession	MD-OS	12	9	NS

	MD-PRM	6	9

	CPO	5	8

	PT	9	7

	Oth	2	2


	PR n=15	GR n=15	p Value

Age: mean (SD)	59.1 (7.2)	51.7 (10.8)	0.04*

Gender, number of patients: M (F)	10 (5)	8 (7)	0.46**

Time since stroke: mean (SD) and range (months)	40.7 (42.6) 6–165	31.3 (28.2) 6–116	0.74*

Ratio of ischaemic to primary intracerebral haemorrhagic stroke	12:3	13:2	–

ARAT: mean (SD) (max 57)	32.9 (8.5)	52.7 (5.49)	<0.01*

Grip mean: (SD) (% unaffected side)	41.4 (14.3)	74.6 (18.57)	<0.01*

Motricity index: mean (SD) (% unaffected side)	65.2 (11.4)	91.9 (4.2)	<0.01*

NHPT: mean (SD) (% unaffected side)	5.8 (5.9)	53.1 (23.7)	<0.01*


Characteristics	Patient 1	Patient 2

Age at first visit to fertility clinic	28 years	31 years

Pubarche (spontaneous)	at 14 years	at 15 years

Heights	170 cm	156 cm

Weight	65 kg	53 kg

Breast development by Tanner scale	Stage V	Stage IV

Sense of odors	Normal	Normal

Karyotype	46, XX	46, XX

MRI of the pituitary	Size: 10 mm x 6 mm x16 mm. Signs of signal reduction in the right half of the posterior pituitary (4 mm x 3 mm x 2 mm), depicting a cyst.	Size: 3.5 mm x 5 mm x 9 mm showing signs of moderate pituitary hypoplasia

Vaginal ultrasound	Uterus: 27 mm x 43 mm x 30 mmEndometrium: 2.3 mmRight ovary: 18 mm x 16 mm with 4 follicles (6 to 8 mm).Left ovary: 17 mm x 18 mm with 5 follicles (6 to 7 mm).Moderate hypoplasia of the uterus and ovaries.	Uterus: 35 mm x 22 mm x30 mmEndometrium: 1.8 mmRight ovary: 21 mm x 18 mm with 3 follicles (3 to 5 mm)Left ovary: 17 mm x 18 mm with 5 follicles (6 to 7 mm). Moderate hypoplasia of the ovaries.

Partner characteristics for IVF with ICSI	Ejaculate volume: 2 mlSperm concentration: 39x106/ml,Motile sperms: 3 %Normal forms by Kruger strict criteria: 2 %.	Ejaculate volume: 5 mlSperm concentration: 31x106/mlMotile sperms: NoneNormal forms by Kruger strict criteria: 1 %.


Age	Gender	Handedness	Brain areas with Foci

38	Male	Right	Right temporal lobe

54	Female	Right	Left amygdala, left hippocampus, right hippocampus

42	Male	Right	Left amygdala, left hippocampus

35	Male	Left	Right amygdala, right hippocampus

41	Male	Right	Left hippocampus, left frontal lobe

21	Female	Right	Left amygdala, left hippocampus

24	Female	Right	Right amygdala, right hippocampus, right frontal lobe

23	Male	Right	Right amygdala, right hippocampus

54	Female	Right	Left hippocampus

56	Female	Right	Right occipetal lobe

40	Female	Right	Right amygdala, right hippocampus

54	Female	Right	Right hippocampus

20	Male	Right	Right temporal lobe

53	Female	Right	Right amygdala, right hippocampus, left amygdala, left hippocampus


Sampling subjects	Source of sample	Number of sample screened	Positive samples on microbiological analysis	Positive samples on biochemical analysis	Genus specific PCR positive	Serotype identified by multiplex PCR

Human infants (<5 years)	Male	200	23	2	2	Salmonella Enteritidis (n=1), other Salmonella serotypes (n=1)

	Female	200	30	3	3	Salmonella Enteritidis (n=1), Salmonella Typhimurium (n=2)

Young animals (<6 months)	Canine	25	8	2	2	Other Salmonella serotypes (n=2)

	Bovine	15	3	0	0	ND

	Equine	10	0	0	0	ND

Fresh vegetables	Cilantro leaves	10	5	1	1	Salmonella Typhimurium (n=1)

	Tomato	20	3	1	1	Other Salmonella serotypes (n=1)

	Mint leaves	20	0	0	0	ND

Sewage waste		50	20	5	5	Other Salmonella serotypes (n=5)


 	Waca Playa (Bolivia)	Pitumarca (Peru)

Human Development Index	0.36 a	0.51 b

Life expectancy (years)	52.4 a	70.0 b

National social health security	SUMI: coverage for pregnant women and children under age 5	SIS: coverage for all adult population living in poverty or extreme poverty

Community biomedical facilities	Rudimentary medical post with one auxiliary nurse provides ambulatory health care to 20 villages. Approximately one visit by auxiliary nurse every two months to each village.c	Health center with 11 health professionals, including one medical doctor. One visit by a nurse per month to each village. 4 to 6 health workers trained in each village. c

Distance from community to villages where households were interviewed (km)	5 to 9 c	4 to 5 c

Distance from community to nearest hospital (km)	approximately 40 (dirt road) c	35 (paved road) c

Beds per inhabitant (number)	0.66 d	0.84 e


Panel	Criteria

Professional	• Be 18 years or older, AND• Live in Australia, Canada, Ireland, New Zealand, United Kingdom or the United States, AND• Have a minimum of 2 years’ experience specialising in research on or treatment of problem gambling.

Lived experience	• Be 18 years or older, AND• Live in Australia, Canada, Ireland, New Zealand, United Kingdom or the United States, AND• Have a lived experience of gambling problems, but are currently recovered and have experience in an advocacy or peer support role, OR• Are a family member or friend who has assisted a person with a gambling problem and have experience in an advocacy or peer support role.


Case study

 	DHp: 9 contacts out of 46	RR: 24 contacts out of 68

 	Contacts among top 9	p-value	Contacts among top 24	p-value

MI	3	0.2503	9	0.4864929

MIc	4	0.0800	9	0.4864929


Evaluation	Days after Enrolment

	0	3–4	13–15	24–32	84–92

Notification to study center	X

Entry criteria	X

Written Informed Consent	X*	X*

Demography	X

Clinical data	X	X	X	X	X

(Serious) Adverse events	X	X	X	X	X

Mortality		X	X	X	X

Blood culture	X

Urine culture	X			X

Randomization and allocation to study treatment		X

End of treatment assessment			X

Contact – in person	X	X		X

Contact – by phone			X		X


Follow up point	Variables in the equation	OR (95% CI)	Nagelkerke*	sn/sp

14 days (n = 235)	Pain for >30 days in year	3.2 (1.9 to 5.6)	0.26	90/25

Pain (for every 1 point increase)	0.8 (0.8 to 0.9)

30 days (n = 131)	Duration	 	0.32	92/29

< 1 month	1.0

1–3 months	5.6 (1.8 to 17.0)

>3 months	2.4(1.1 to 5.5)

90 days (n = 150)	 	 	0.45	94/23

Duration

< 1 month	1.0

1–3 months	9.3 (3.0 to 29.0)

 	>3 months	3.0(1.3 to 7.0)


Chemistry	Selection	Counter-selection	Targeted or identified targets	Number of cycles	Reference

Mammalian Cells

DNA	YPEN-1	N9	Pigpen	8	[58]

DNA	B lymphoma cells	No	ND	10	[71]

DNA	Differenciated PC12	PC12	ND	6	[60]

DNA	U251	No	Tenascin-C	21	[67]

2′F-Py RNA	CHO-kinin B1 receptor	No	Kinin B1 receptor	8	[72]

2′F-Py RNA	PC12-MEN2A	PC12/PC12-MEN2A	RET	15	[16]

2′F-Py RNA	CHO-TbRIII	CHO	TbRIII	11	[73]

DNA	aMSCs	No	ND	11	[74]

DNA	CCRF-CEM	Ramos	PTK7	20	[65,70]

DNA	Ramos	No	mmunoglobin heavy mu chain	23	[69,75]

DNA	SAOS-2 osteoblasts	No	ND	10	[68]

DNA	MEAR	BNL	Non-muscle myosin	16	[62]

DNA	NCI-H69	NCI-H661	ND	25	[76]

DNA	EPCs	No	ND	10	[77]

DNA	iDC (mDC)	mDC (iDC)	Several (see reference)	10	[66]

DNA	Burkitt lymphoma cells	No	ND	10	[59]

DNA	A549	HLAMP	ND	25	[78]

DNA	HL60	NB4	ND	16	[64]

2′F-Py RNA	U87MG	T98G	ND	14	[79]

DNA	CT26-E2	CT26	Virus Glycoprotein E2	13	[80]

DNA	Infected A549	Non-infected A549	ND	13	[63]

RNA	SKBR3	SKBR3/siHER-2/MDAMB231	HER-2	20	[81]

DNA	HEK293T-TLR2-Fc	No	TLR2	7	[82]

DNA	Vaccinia virus-infected HeLa	Non-infected HeLa	Hemagglutinin	20	[61]

2′F-Py RNA	HET-SR-1	HET-SR	ND	10	[83]

DNA	Tov-21G/CAOV-3	HeLa	ND	22	[84]

DNA	DLD-1/HCT 116	HCT 116/HT-29	ND	16	[85]

DNA	NIH3T3	IL-17RA-deficient NIH3T3	IL-17RA	12	[86]

Viruses

2′NH2-Py RNA	Human cytomegalovirus	No	Glycoprotein B and H	16	[57]

RNA	Influenza A panama virus	Influenza A Aichi Virus	Haemagglutinin	10	[87]

Bacteria

DNA	B. anthracis spores	No	ND	4	[55]

DNA	M. Tuberculosis H37Rv	M. Tuberculosis BCG	ND	10	[88]

DNA	L. Acidophilus	No	S-layer protein	8	[89]

DNA	S. aureus	Streptococcus/S. epidermidis	ND	5	[90]

DNA	C. Jejuni	Non relevant mix	ND	10	[91]

DNA	P. aeruginosa	S. Maltophilia/A. Baumannii	ND	16	[92]

Parasites

RNA	T. brucei	No	ND	12	[56]

2′F-Py RNA	T. cruzi trypomastigote	Epimastigote	Several (see reference)	8	[93]

2′NH2-Py RNA	T. brucei	No	ND	13	[94]


Venue	Cluster 1 (N = 2715) low-use mean	Cluster 2 (N = 1236) high-use mean	Importance (%)

Sports centre	1.20	2.69	1.00

Cinema or theatre	1.35	2.73	1.00

Vending machine	1.19	2.62	1.00

Street stall or small shop	1.70	2.9	1.00

Newsagent	1.13	2.68	1.00

Petrol station	1.23	2.64	1.00

Cafe	1.81	2.94	1.00

A fast food restaurant (KFC, McDonalds)	1.76	2.83	0.99

A convenience store (7-eleven)	1.84	2.99	0.94


	Group A (n = 31) (Peg-IFNα + RBV + placebo)	Group B (n = 31) (Peg-IFNα + RBV + Silybin, Vit E, phospholipids)	P Value

Psychological disorders	14%	12%	NS

Hypercholesterolemia	16%	32%	P < 0.01

Fatigue	48%	44%	NS

Headache	41%	42%	NS

Musculoskeletal pain	54%	35%	P < 0.01

Myalgia	58%	32%	P < 0.01

Hypertriglyceridemia	44%	30%	P < 0.01

Nausea	31%	24%	P < 0.05

Anorexia	6%	8%	NS

Irritability	30%	22%	P < 0.05

Hyperglycemia	13%	8%	P < 0.05

Weight loss	12%	7%	P < 0.05

Decrease of hemoglobin values at the end of treatment	from 13.6 g/dL (range 11.4–14.4) to 11.6 g/dL (range 10.4–14.2 g/dL)	from 13.6 g/dL (range 11.6–15.9 g/dL) to 10.6 (range 10.4–12.8 g/dL)	NS


MIGS ID	Property	Term	Evidence code

	Current classification	Domain Bacteria	TAS [15]

Phylum Proteobacteria	TAS [16]

Class Betaproteobacteria	TAS [17,18]

Order Burkholderiales	TAS [18,19]

Family Burkholderiaceae	TAS [18,20]

Genus Burkholderia	TAS [21-23]

Species Burkholderia sp.	IDA

Strain WSM2230	IDA

	Gram stain	Negative	IDA

	Cell shape	Rod	IDA

	Motility	Motile	IDA

	Sporulation	Non-sporulating	NAS

	Temperature range	Mesophile	IDA

	Optimum temperature	30°C	IDA

	Salinity	Non-halophile	IDA

MIGS-22	Oxygen requirement	Aerobic	IDA

	Carbon source	Varied	IDA

	Energy source	Chemoorganotroph	NAS

MIGS-6	Habitat	Soil, root nodule, on host	IDA

MIGS-15	Biotic relationship	Free living, symbiotic	IDA

MIGS-14	Pathogenicity	Non-pathogenic	IDA

	Biosafety level	1	IDA

	Isolation	Root nodule of Kennedia coccinea	IDA

MIGS-4	Geographic location	Karijini National Park, Australia	IDA

MIGS-5	Soil collection date	September 2001	IDA

MIGS-4.1MIGS-4.2	LatitudeLongitude	117.99-22.5	IDAIDA

MIGS-4.3	Depth	0-10 cm	IDA

MIGS-4.4	Altitude	Not reported


	HIV+ group only

Median Nadir CD4-T+ cells/μL	198	IQR: 31-279

Median current CD4-T+ cells/μL	597	IQR: 342-748

% Plasma undetectable HIV RNA (<50 cp/mL)1	95.5%	-

% CSF Undetectable HIV RNA (<50 cp/mL)2	97.6%	-

Median HIV duration (years)	20.5	IQR: 14-25

% AIDS status (CDC 1993)	70.5%	-

% With past AIDS defining illness	53%	-

Median current cART duration (months)	30	IQR: 12-54

% MSM as HIV risk factor	89%	-

Average educational level (years)	13.82	SD: 2.95

% Current hAND	61.3%	-

% Past hAND	31.8%	-

% APOE any ε4 allele carriers	30.9% (N = 13)	-

% APOE ε4/ε4 allele carriers	7.1% (N = 3)	-

% APOE ε2/ε3 allele carriers	7.1% (N = 3)	-

% APOE ε3/ε3 allele carriers	61.9% (N = 26)	-


		ALL

		(n = 504)

Age(years)	Median(IQR)	71 (59–80)

	<40 yr	47 (9.3)

	≧40 yr. <60 yr	88 (17.5)

	≧60 yr. <80 yr	236 (46.8)

	≧80 yr	133 (26.4)

Male		255 (50.6)

Disease	Adrenocortical insufficiency	264 (52.4)

Adrenal crisis	194 (38.5)

Secondary adrenocortical insufficiency	28 (5.6)

Post-procedural adrenocortical hypofunction	10 (2.0)

Steroid withdrawal syndrome	5 (1.0)

Iatrogenic adrenocortical insufficiency	3 (0.6)

Department	Internal medicine	255 (50.6)

Neurosurgery	94 (18.7)

Urology	18 (3.6)

Others	137 (27.2)

Season	Jan - March	149 (29.6)

April–June	112 (22.2)

July - Sept	112 (22.2)

Oct - Dec	131 (26.0)


Taxon	Species	Isoenzyme	Sequence identity, %

Mammals	Homo sapiens - Microcebus murinus	GAPD-1	91

	Homo sapiens - Callitrix jacchus	GAPD-2	94

Teleosts	Tetraodon nigroviridis - Takifugu rubripes	GAPD-1	94

	Tetraodon nigroviridis - Takifugu rubripes	GAPD-2	92

Insects	Drosophila ananassae - Drosophila virilis	GAPD	87


Predictor variable	Odds Ratio	p-value	95% Confidence Interval

Health declaration (N = 1459)

 IVQ33/ITQ50: confidence	0.69	0.017	(0.51, 0.94)

Depression coding: IVQ33ITQ50 model (N = 1459)

 Non-professional background	4.39	0.010	(1.44, 13.40)

 IVQ33/ITQ50: confidence	0.52	0.013	(0.31, 0.87)

Depression coding: ITQ100 model (N = 1619)

 Non-professional background	4.78	0.001	(1.97, 11.60)


Client Mode	Indicates	Server Mode	Indicates

INIT	Initialization.	INIT	Initialization.

SPEAKER	Client is speaker.	SPEAKERS_TURN	Signal creation

HEARER	Client is hearer.	HEARERS_TURN	Signal recognition

FEEDBACK	Client is receiving feedback.	FEEDBACK	Clients are receiving feedback.


Specimen Source Treatment	n	MIC Range	MIC50 (μg/mL)	MIC90 (μg/mL)

Minimum (μg/mL)	Maximum (μg/mL)

Urogenital

 Gepotidacin 1500 mg	30	≤0.06	1	0.12	0.5

 Gepotidacin 3000 mg	39	≤0.06	1	0.25	0.5

 Gepotidacin total	69	≤0.06	1	0.12	0.5

Pharyngeal

 Gepotidacin 1500 mg	...	...	...	...	...

 Gepotidacin 3000 mg	2a	≤0.06	0.12	...	...

 Gepotidacin total	2a	≤0.06	0.12	...	...

Rectal

 Gepotidacin 1500 mg	1	0.12	0.12	...	...

 Gepotidacin 3000 mg	2	0.12	0.25	...	...

 Gepotidacin total	3	0.12	0.25	...	...


	Pre-dictive ethics	Iterative ethics

1	Ethical risks are generally predictable	Ethical risks may NOT be predictable

2	Ethical procedures should be pre-specified - Ethics as ‘requirement’	Ethical procedures should be emergent to take into account the unfolding context - Ethics as ‘process’

3	Treats participants as being ‘subject to’ research	Treats participants as being ‘subjective participants within’ research

4	Ethics reviews aim to protect participants	Ethics reviews aim to help researchers to think sensitively about how to maintain an ethical stance towards and with research participants

5	Ethics reviews aim to evaluate researchers	Ethics reviews aim to work with researchers to explore ethical concerns

6	Ethics reviews ‘apply’ codes of conduct and treat ethics as a set of ‘accountable standards’	Ethics reviews analyse ethical concerns with researchers in relation to the specific research context

7	Researchers treated as independent from practices of data collection and regarded as implementing a research protocol	Researchers seen as reflexive participants within research

8	Work with a binary of ‘ethical’/‘non-ethical’	Treat ethical problems as multidimensional and contextually framed


Patient	Angiographic findings*	gradient reduction**	Number of additional Revisions	Follow up

1	HV, PV, SMV occluded	17 → 8	2	2 years

2	HV occluded	30 → 7	1	4 years

3	HV occluded	23 → 10	3	2 years

4	HV occluded	29 → 12	2	12 years

5	HV occluded	46 → 6	1	5 years

6	HV, PV, IVC occluded	35 → 6	8	7 years

7	HV occluded	32 → 6	4	11 years

8	HV occluded	25 → 10	1	3 years

9	HV occluded	20 → 8	2	6 years

10	HV occluded	32 → 3	0	3 years

11	HV occluded	31 → 9	3	3 years

12	HV occluded	10 → 4	6	10 years

13	HV occluded	38 → 6	0	1/2 year


	Current	Desired	Gap	Academic Gap	Community Gap

Estimating incremental risk incurred by conditional risk factors	3.84	4.59	0.75	0.83	0.67

Estimating cardiovascular risk in primary prevention	4.14	4.75	0.61	0.73	0.48

Estimating incremental risk incurred by predisposing risk factors	4.07	4.67	0.60	0.68	0.52

Identifying <underline>conditional</underline> cardiovascular risk factors	4.07	4.65	0.59	0.67	0.51

Estimating cardiovascular risk in secondary prevention	4.29	4.75	0.46	0.56	0.36

Identifying predisposing cardiovascular risk factors	4.41	4.78	0.37	0.45	0.29

Identifying <underline>major independent</underline> cardiovascular risk factors	4.49	4.79	0.30	0.37	0.23


Substances	Retention time	OLALPZER	OLALPVIT

(min)	Area (%)	Area (%)

α-Thujene	12.6	3.7	-

α-Pinene	12.9	1.7	10.1

Camphene	13.6	0.2	-

Sabinene	14.7	13.8	1.2

β-Pinene	14.8	3.0	35.3

β-Myrcene	15.4	1.1	-

Phellandrene	16.1	0.3	-

α-Terpinene	16.6	4.0	-

ρ-Cymene	16.9	4.8	-

Limonene	17.1	1.8	1.5

1,8-Cineol	17.2	15.3	-

α-Terpinolene	-	2.0	-

cis-Sabinene	20	2.2	-

Terpinen-4-ol	23.2	19.7	-

α-Cubebene	29.0	-	2.1

Copaene	30	-	2.4

β-Cubebene	30.4	-	2.4

β-Caryophyllene	31.5	3.2	1.0

β-Gurjunene	32.4	-	1.7

Aromadendrene	32.8	-	0.7

cis-Muurola-4(14),5-diene	33.1	-	0.6

Germacrene-D	33.4	-	0.6

epi-Bicyclosesquiphellandrene	33.8	-	1.0

epi-Cubebol	33.9	-	5.0

Calamenene	34.7	-	2.0

Cadina-1(2),4-diene	35.0	 	0.8

Viridiflorol	37.2	 	1.75

1-epi-Cubenol	37.8	 	1.43

1,10-di-epi-Cubenol	38.2	 	1.24

Caryophyllene oxide	36.5	1.9	-

Others	-	21.2	27.2


Patient	Age	First presentation	Patient interval	Residential areaa	Full-time job	Cohabitant children

Pre-disaster

 1	(50–65]	Apr.-Jun. 2007	120 months	Voluntary evacuation zone	Yes	No

 2	(65-	Apr.-Jun. 2008	48 months	Voluntary evacuation zone	No	No

 3	(50–65]	Sep.-Nov. 2008	18 months	Voluntary evacuation zone	No	No

 4	(65-	Dec. 2008-Feb. 2009	120 months	Non-evacuation zone	No	Yes

 5	−50]	Sep.-Nov. 2009	36 months	Mandatory evacuation zone	Yes	Yes

Post-disaster

 1	(50–65]	Dec. 2011-Feb. 2012	24 months	Non-evacuation zone	No	Yes

 2	(65-	Jun.-Aug. 2012	18 months	Non-evacuation zone	No	No

 3	(50–65]	Sep.-Nov. 2012	17 months	Voluntary evacuation zone	Yes	No

 4	(65-	Sep.-Nov. 2012	12 months	Voluntary evacuation zone	No	No

 5	−50]	Dec. 2012-Feb. 2013	12 months	Voluntary evacuation zone	No	No

 6	(65-	Dec. 2012-Feb. 2013	25 months	Voluntary evacuation zone	Yes	No

 7	(65-	Mar.-May 2013	24 months	Voluntary evacuation zone	No	No

 8	(65-	Mar.-May 2014	12 months	Non-evacuation zone	No	No

 9	−50]	Jun.-Aug. 2014	13 months	Non-evacuation zone	Yes	Yes

 10	(65-	Sep.-Nov. 2014	24 months	Voluntary evacuation zone	No	No

 11	(65-	Sep.-Nov. 2014	84 months	Voluntary evacuation zone	No	Yes

 12	−50]	Sep.-Nov. 2014	24 months	Voluntary evacuation zone	No	No

 13	(65-	Dec. 2014-Feb. 2015	24 months	Voluntary evacuation zone	No	No

 14	(50–65]	Jun.-Aug. 2015	24 months	Mandatory evacuation zone	No	No

 15	(65-	Sep.-Nov. 2015	24 months	Voluntary evacuation zone	No	No

 16	(65-	Sep.-Nov. 2015	120 months	Voluntary evacuation zone	No	No

 17	(50–65]	Sep.-Nov. 2015	13 months	Mandatory evacuation zone	No	Yes

 18	(50–65]	Dec. 2015-Feb. 2016	12 months	Voluntary evacuation zone	Yes	No


Symptom	n 	%

Bloated stomach 	56	61.5

Anemia	48	52.7

Weight loss	44	48.3

Diarrhea	36	39.6

Vomiting	18	19.8

Other symptoms/signs	31	34.1


 	P value	OR	95% CI

Clavicle tunnel position (x-axis)	.454	1.19	0.77–2.00

Duration (within 5 days)	.002	1.82	1.32–2.87

Initial reduction (Good)	.003	59.71	6.71–1855.80


Gene1	Gene product2	Reference

<underline>A: Containing a TTA codon</underline>

SCO4262	Hypothetical protein	[55]

SCO6638	Hypothetical protein	[55]

<underline>B: Regulated by a TTA-containing gene</underline>

<underline>By adpA</underline>

SCO0762	Protease inhibitor	[55]

<underline>By SCO4263</underline>

SCO4246	Hypothetical protein	[55]

SCO4251	Putative secreted protein	This study

SCO4252	Hypothetical protein	This study

SCO4253	Conserved hypothetical protein	This study

<underline>By act II-ORF4</underline>

SCO5071	Hydroxylacyl-CoA dehydrogenase, ActVI-ORFA	[14]

SCO5073	Putative oxidoreductase, ActVI-ORF2	[14]

SCO5074	Putative dehydratase, ActVI-ORF3	[14]

SCO5075	Putative oxidoreductase, ActVI-ORF4	[14]

SCO5078	Hypothetical protein	[14]

SCO5079	Conserved hypothetical protein	[14]

SCO5086	Ketoacyl reductase, ActIII	[14]

SCO5088	Polyketide beta-ketoacyl synthase, ActI-ORF2	[14]

SCO5090	Actinorhodin polyketide cyclase/dehdratase, ActVII	[14]

<underline>By redZ</underline>

SCO5895	Putative methyltransferase, RedI	[20]

<underline>C: In a putative operon with a TTA-containing gene</underline>

SCO0392	Putative methyltransferase	[31]

SCO0395	Putative epimerase/dehydratase	[31]

SCO0400	Putative epimerase	[31]

SCO0401	Putative aminotransferase	[31]

SCO0991	Conserved hypothetical protein	[31]

SCO0994	Integral membrane protein	[31]

SCO0995	Probable methyltransferase	[31]

SCO6637	Hypothetical protein	[31]


Domain	Question	Key process probed	Significance

Background	Previous occupation?	Previous cognitive/auditory function, noise exposure	Correct interpretation of hearing tests

Previous level of musical training and interest, early language development and education?	Prior auditory expertise	Correct interpretation of hearing tests

Course	When was hearing impairment first noticed?	Duration of impairment (relative to cognitive decline)	Nature of underlying disease process

Has this deteriorated, fluctuated or improved since onset?	Tempo of impairment	Nature of underlying disease process

Symptoms

 Sound detection	Is there a lack of reaction to sounds?	Impaired sound detection	May signify deafness (any cause)

Is there a tendency to turn up the volume of radio or TV or to ask people to speak louder?	Impaired sound detection	May signify deafness (any cause)

Is there a complaint that increasing volume makes sounds suddenly seem too loud?	Impaired sound detection	May signify cochlear pathology (‘loudness recruitment’)

 Abnormal auditory perception: deficient	Is there particular difficulty following conversations in background noise or over a noisy telephone line?	Auditory scene analysis	May signify a cerebral disorder (e.g., Alzheimer’s disease) in absence of significant hearing loss

Is there difficulty locating sounds (e.g., an alarm or mobile, a person speaking in same the room)?	Auditory scene analysis	May signify a cerebral disorder in absence of significant hearing loss

Is there particular difficulty understanding speech versus other sounds?	Feature analysis	May signify word deafness

Is there more difficulty understanding less familiar accents?	Apperceptive processing	May signify a cerebral disorder in absence of significant hearing loss

Is there more difficulty understanding a person’s tone of voice (e.g., angry or upset)?	Apperceptive and emotional processing	May signify a frontotemporal dementia in appropriate context

Has there been any problem recognising familiar voices, music or other sounds?	Semantic processing	May signify auditory agnosia or semantic dementia, in appropriate context

 Abnormal auditory perception: excessive	Is there a persistent complaint of buzzing or ringing in the ears?	Tinnitus	May be peripheral or central in origin

Are other sounds ever heard when no sounds are present?	Formed hallucinations	May signify Lewy body disease, in appropriate context

 Abnormal auditory behaviour	Is there intolerance to moderately loud sounds or particular sounds?	Hyperacusis	May signify a frontotemporal dementia in appropriate context

Has there been any change in liking for or interest in music or other sounds?	Auditory hedonic processing	May signify a frontotemporal dementia in appropriate context


Level of education	Specialization/means of accessing information	n	Heard about aflatoxins

Frequency (% of n)

 	Specialization

Low	Life/social sciences	0	0 (0)

None/other fields	110	12 (11)

High	Life/social sciences	132	55 (42)

None/other fields	16	4 (25)

Total	258	71 (28)

 	Means of accessing information

Low	Reading	3	1 (33)

Mass media (radio/TV)	69	6 (9)

Seminars/experts	11	1 (9)

Friends/neighbours	8	3 (37)

High	Reading	3	2 (67)

Mass media (radio/TV)	69	43 (91)

Seminars/experts	11	10 (91)

Friends/neighbours	8	5 (63)


Biological process		Number of genes affected by FOS*

Mitochondria	Complex I	27

	Complex II	5

	Complex III	2

	Complex IV	13

	Complex V	21

	Metabolism and TCA cycle	53

	Mitochondrial ribosomes	33

	Protein transport	11

	Miscellaneous	12

Protein turnover	Protein degradation	31

	Translation	44

	Protein maturation	32

	Miscellaneous	6

Transcription	Chromatin related	22

	mRNA metabolism	7

	Transcription	26

	Miscellaneous	6

Cell turnover	Apoptosis	19

	Growth/Differentiation	16

Mucosal barrier		30

Cytoskeleton		26

Transport		20

Oxidative stress		16

Vesicle related		10

Peptide hormones		6

Other†		503

		997


Beat type	Number of beats in Test data set	Number of beats in Training data set	Possession rate (%)

Normal	54516	5000	70.2573

LBBB	6036	1000	7.7746

RBBB	5410	1000	6.9889

PVC	5293	1000	6.8166

APB	1896	1000	2.4407

PB	2702	1000	3.4853

Total	75853	10000	97.76


 	 	 Attentional bias index to fearful expression

 	 	 12 months 	 18 months 	 24 months 	 36 months

Fear scale (IBQ-R or ECBQ)	12 months	−.020	-	-	-

 	18 months	.240	−.231	-	-

 	24 months	−.100	−.335	−.262	-

 	36 months	.174	−.463	.105	.017

Average score of scales loading on Negative Affect	12 months	.527**	-	-	-

 	18 months	.403	−.083	-	-

 	24 months	.222	−.286	−.023	-

 	36 months	.309	−.276	−.125	.146


	Pearls	Cheese matrix

Total solids (%)	79.09	70.37

Fat (%)	28	32

FDM (%)	35.4	45.5

Free leucine (%)	1.0	–


Stud #	Institution	Parents	Habitat

Stud #	Sex	XXL	MIN	QIO

358	WOLONG	Wild	-	0	0	1.0

425	CHENGDU	298	M	0	1.0	0

314	F	0.5	0	0.5

557	WOLONG	399	M	0	0	1.0

446	F	0	1.0	0


Name	Sequences (5'-3')	Description

OP-F	TCTGGAATGGCTGAAGAAGACG	Forward primer for the actin gene of T. vaginalis in the first stage

OP-R	CAGGGTACATCGTATTGGTC	Reverse primer for the actin gene of T. vaginalis in the first stage

IP-F	CAGACACTCGTTATCG	Forward primer for the actin gene of T. vaginalis in the second stage

IP-R	CGGTGAACGATGGATG	Reverse primer for the actin gene of T. vaginalis in the second stage


Drugs	Direct Inhibition of HERG K+ Channel	Inhibition of HERG K+ Channel Trafficking

Phenothiazines	+	?

Pentamidine	-	+

Geldalamicin	-	+

Arsenic Trioxide	-	+

Fluoxetine, Norfluoxetine	+	+

Ketoconazole	+	+

Digitoxin, Ouabain, Digoxin	-	+

Sparfluoxacin, Ciprofloxacin, Ofloxacin	+	-

Amsacrin	+	-

Probucol	-	+

Cisapride	+


Variant	p-valuea	Annotation

rs1800361	3.01E-04	nonsynonymous

rs145497019	1.20E-05	nonsynonymous

rs1800362	9.71E-06	nonsynonymous

rs1800368	9.71E-06	nonsynonymous

rs138629441	5.79E-06	nonsynonymous

rs143152201	3.19E-06	nonsynonymous

9:97869388	2.33E-06	nonsynonymous

FANCC	2.27E-06b

9:97887391	2.27E-06	nonsynonymous

rs1800367	2.27E-06	nonsynonymous

9:97876956	2.20E-06	nonsynonymous

rs140687953	1.87E-06	nonsynonymous

rs140781259	1.70E-06	nonsynonymous

9:97934335	1.66E-06	nonsynonymous

rs1800366	1.65E-06	nonsynonymous

rs121917783	1.59E-06	stop-gain

rs1800365	1.48E-06	nonsynonymous


 	Total	Blood	Urine	Abscess drainage	Other

Gram-positivea	90	44	27	25	18

Streptococcus pneumonia	29	14	20b	0	5

Alpha hemolytic streptococci	18	7	0	6	7

Group A/C/G streptococci	13	6	0	9	1

Group B streptococci	2	1	0	1	0

Enterococci	6	3	2	0	2

Staphylococcus aureus	20	11	4	9	3

Staphylococcus caprae	1	1	0	0	0

Aerococcus viridans	1	1	1	0	0

Gram-negativea	55	32	21	8	9

Escherichia coli	27	19	13	3	3

Klebsiella	10	6	5	0	1

Enterobacter	1	1	0	0	0

Proteus	2	0	0	1	1

Other Enterobacteriaceae	5	2	3	1	0

Pseudomonas aeruginosa	2	1	0	1	1

Stenotrophomonas maltophilia	1	0	0	1	0

Neisseriae meningitides	2	2	0	0	0

Haemophilus influenzae	2	1	0	0	1

Haemophilus parainfluenzae	2	0	0	0	2

Unspecified gram negative rods	1	0	0	1	0

Anaerobic bacteria	17	6	0	3	9

Clostridium species	5	2	0	0	3c

Bacteroides species	5	3	0	1	2

Prevotella	4	0	0	2	2

Slackia exigua	1	1	0	0	0

Fusobacterium	1	0	0	0	1

Unspecified gram positive rods	1	0	0	0	1

Other	9	0	0	3	6

Candida species	7	0	0	3	4

Aspergillus species	1	0	0	0	1

Influenzavirus A	1	0	0	0	1

Patients with ≥1 positive test	129	74	40	23	29


Grade of fibrosis	Histological changes

0	Normal lung

1	Minimal fibrous thickening of alveolar/bronchial walls

2	Intermediary stage between 1 and 3

3	Moderate thickening of walls without obvious damage to the lung architecture

4	Intermediary stage between 3 and 5

5	Increased fibrosis with definite damage to lung structure and formation of fibrous bands or small fibrous masses

6	Intermediary stage between 5 and 7

7	Severe distortion of structure and large fibrous areas; honeycombing lung is placed in this category

8	Total fibrous obliteration of the field


Cell lines	Tissue	Bozepinib

IC50 (μM)	TI

MCF-7a	Breast cancer	0,355 ± 0,011	5,14

MDA-MB 231a	Breast cancer	0,166 ± 0,063	11

MDA-MB 468	Breast cancer	0,850 ± 0,003	2,14

SKBR-3	Breast cancer	0,330 ± 0,003	5,53

MCF-10Aa	Normal breast	1,825 ± 0,003	NDb

Caco-2	Colon cancer	0,631 ± 0,008	3,18

T-84	Colon cancer	1,019 ± 0,281	1,97

HT-29	Colon cancer	1,352 ± 0,281	1,48

SW-480	Colon cancer	0,235 ± 0,011	8,56

HCT-116	Colon cancer	0,570 ± 0,020	3,52

CCD-18Co	Normal colon	2,012 ± 0,012	NDb


	Respondents agreeing to each statement

	Women%	Men%	p-value*

There is often violence at parties	25	14	< 0.001

Property is often destroyed at parties	43	39	0.08

There are often accidents with physical injury at parties	54	46	0.008

I often baby-sit drunk friends	80	83	0.09

I feel I can talk to a friend about his/her alcohol habits	89	90	0.26

My sleep is often disturbed due to others partying	29	21	0.001

My study habits are often disturbed due to others partying	17	15	0.15


Complications and outcomes	Conventional (n = 40)	Restrictive (n = 41)

Total complications	43	45

Cardiovascular complications

 Atrial fibrillation	2 (4.6)	1 (2.2)

 Hypertensive crisis	4 (9.3)	0 (0)

 Pulmonary thromboembolism	0 (0)	1 (2.2)

 Total	6 (13.9)	2 (4.4)

Tissue-healing complications

 Evisceration	2 (4.6)	0 (0)

 Anastomotic leak	2 (4.6)	1 (2.4)

 Total	4 (9.3)	1 (2.4)

Infectious complications

 Nosocomial pneumonia	4 (9.3)	6 (13.3)

 Occult septic shock	1 (2.3)	0 (0)

 Peritonitis	2 (4.6)	0 (0)

 Blood stream infection	0 (0)	1 (2.2)

 Wound abscess	2 (4.6)	0 (0)

 Total	9	7

Other complications

 Extubation failure	1 (2.3)	0 (0)

 Renal dysfunction	1 (2.3)	0 (0)

 Gastrointestinal dysfunction	3 (6.9)	1 (2.2)

 Total	5	1

Total number of major complications	24	11

Number of patients with complications	18 (41.8)	9 (20.0)*

Number of complications per patient	0.55	0.24

Outcomes

 LOS in the ICU	2.0 [1.0 to 4.0]	2.0 [2.0 to 5.0]

 LOS in the hospital	6.0 [4.0 to 9.0]	6.0 [4 to 10]

 30-day mortality rate	2 (4.6)	0 (0)

 60-day mortality rate	3 (6.9)	1 (2.2)


Type of cost	Identification	Measurement	Valuation

	Categories	Costing method	Sources of data	Valuation method	Sources of data

Recurrent

Personnel	Administration and management, clinical staff (doctors, nurses, lay workers*), and support staff (cleaning)	Percentage of time spent on different activities	Observation** and semi-structured interviews with providers	Total remuneration package costs	Provider expenditure reports

Supplies	Sputum and culture tests, x-rays and drugs	Quantity consumed	Patient records	Market prices	Provincial and private laboratories and pharmacy price lists

Vehicle operating and maintenance	Vehicle running costs	Number of kilometres travelled	Vehicle logbook, interview with clinic manager	Actual expenditure on fuel, oil and maintenance	Automobile Association rates

Building operating and maintenance	Overheads (water, electricity, telephone, fax, stationeries etc)	Proportion of total visits for which TB patients accounted	Actual costs from facility records, interview with clinic manager	Actual expenditure	Provider expenditure reports

Capital†

Buildings	Offices, clinics and hospitals	Proportion of total visits for which TB patients accounted	Interview with clinic manager	Replacement prices	CSIR Building and Construction Technology

Equipment	Furniture, medical and non-medical equipment	Proportion of total visits for which TB patients accounted)	Interview with clinic manager	Replacement prices	Local manufacturers

Vehicles	Vehicles used for TB patients	Vehicle utilisation (km travelled)	Vehicle log book, interview with clinic manager	Replacement prices	Local car dealers

Training	Community "treatment supporters" training	Number of treatment supporters trained	Actual costs from NGO records	Actual expenditure	Provider expenditure reports


	No hypotension	iNIBP	dNIBP	p value

The number of cases in which hypotension was detected faster (n (%))	24	47 (61.8)	29 (38.2)	0.03


	Activity (U/ml)1

Enzymes	Soluble fraction	Insoluble fraction	Percent of activity found in insoluble fraction2	Enzyme amount (mg/ml)3	Specific activity (U/mg enzyme)3	Specific activity relative to the native enzyme3

AMA

 AMA-native	734.4 ± 37.5	9.63 ± 2.29	1.3%	0.47	1563	100%

 AMA-ELK16	66.7 ± 5.1	468.7 ± 12.9	87.5%	0.25	1875	120%

XynB

 XynB-native	398.8 ± 9.7	136.2 ± 17.0	25.4%	0.31	1290	100%

 XynB-ELK16	13.6 ± 0.6	230.0 ± 9.8	94.4%	0.23	991	77%


 	Multivariable logistic regression analysis (n = 362)

Sociodemographic factors	aOR (95%-CI)a

Age (continuous)	1.03 (1.00-1.05)

Health-related factors

Current smoker

 Yes	2.31 (1.27-4.23)

 Not anymore	1.13 (0.66-1.95)

 Never smoked	(Reference)

Ever had a diagnosed depression/depressive mood

 Yes	1.85 (1.12-3.06)

 No	(Reference)

Work-related exposures

Carrying and lifting heavy loads (> 20 kg)

 Frequently	2.69 (1.53-4.75)

 Sometimes	1.26 (0.68-2.34)

 Rarely/Never	(Reference)

Exposure to environmental impacts

 Frequently	2.18 (1.26-3.76)

 Sometimes	1.76 (0.98-3.13)

 Rarely/Never	(Reference)


UniProt ID	Species Name	Protein Name	e-value	Similarity

Q9XKY50	Phytomonas serpens	MURF1	5.3e-148	100.0%

Q33559	Leishmania tarentolae	MURF1	2.7e-109	90.9%

Q8HE85	Trypanosoma sp.	MURF1	3.1e-17	87.6%

Q33547	Blastocrithidia culicis	MURF1	1.2e-16	86.5%

Q33552	Crithidia fasciculata	MURF1	6e-16	88.4%

Q33556	Herpetomonas muscarum	MURF1	5.1e-13	85.0%

Q34937	Leishmania. tarentolae	MURF2	2e-09	60.4%

Q34096	Crithidia fasciculata	MURF2	3.2e-09	56.3%

Q34192	Crithidia oncopelti	NAD5	3.8e-09	54.5%

P48903	Chondrus crispus	NAD2	5.4e-07	57.9%

Q5LRX2	Silicibacter pomeroyi	Putative membrane protein	1.2e-06	58.0%

Q6E773	Saprolegnia ferax	NAD2	1.5e-06	53.8%

Q6SKY5	Speleonectes tulumensis	NAD5	2.3e-06	55.2%

Q5AG49	Candida albicans	Hypothetical protein	3.3e-06	67.7%

Q5AGI5	Candida albicans	Hypothetical protein	7.1e-06	67.9%

Q8SKS6	Ancylostoma duodenale	NAD4	7.4e-06	57.3%

Q85TH7	Melipona bicolor	NAD4	7.7e-06	58.1%

Q33575	Trypanosoma brucei	NAD4	8.7e-06	57.3%

P24499	Trypanosoma brucei brucei	ATP6	1.1e-05	55.4%

Q70NW4	Strongyloides stercoralis	NAD4	1.2e-05	56.7%

Q33570	Trypanosoma cruzi	ATP6	1.5e-05	56.9%

Q5CV17	Cryptosporidium parvum	Hypothetical protein	1.5e-05	61.5%

Q057W5	Buchnera aphidicola	NADH dehydrogenase I chain L	1.9e-05	54.9%

Q8IBJ6	Plasmodium falciparum	Hypothetical protein	2.9e-05	58.4%


Algal species	Molecular technique	Bacterial phyla	Country origin	Reference

CHLOROPHYTA

Bryopsis hypnoides	CLO, FISH	BA, FI, PR (al, ep, ga)	Mexico	Hollants et al. (2011a,b)

Bryopsis pennata	CLO, FISH	BA, FI, PR (al, ep, ga)	Mexico	Hollants et al. (2011a,b)

Caulerpa taxifolia	CLO, RFLP	BA, PR (al, be, de, ga)	4 Countries	Meusnier et al. (2001)

Chara aspera	FISH	AC, BA, PL, PR (al, be, ga)	Germany	Hempel et al. (2008)

Desmidium grevillii	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Halimeda opuntia	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Hyalotheca dissiliens	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Spondylosium pulchrum	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Ulva australis	CLO, DGGE	AC, BA, PL, PR (al, de, ga)	Australia	Longford et al. (2007)

Ulva australis	CLO	AC, BA, CY, PL, PR (al, de, ga), VE	Australia	Burke et al. (2011b)

Ulva australis	CFISH, DGGE	BA, PR (al, ga)	Australia	Tujula et al. (2010)

Ulva intestinalis	CLO, DGGE	AC, BA, PR (al, de, ep, ga), VE	Germany	Lachnit et al. (2011)

Ulva prolifera	CLO, DGGE	AC, BA, CY, FI, FU, PL, PR (al, be, de, ep, ga), SP, VE	China	Liu et al. (2011)

HETEROKONTOPHYTA

Dictyota bartayresiana	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Fucus vesiculosus	CLO, DGGE	BA, CY, PL, PR (al, be, de, ep, ga), VE	Germany	Lachnit et al. (2011)

Laminaria hyperborea	DGGE, FISH	AC, BA, CY, PL, PR (al, be, ga), VE	Norway	Bengtsson et al. (2010)

Laminaria rodriguezii	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Saccharina latissima	CLO, DGGE	BA, PR (al, ga)	Germany	Staufenberger et al. (2008)

RHODOPHYTA

Coralline crustose	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Delisea pulchra	CLO, DGGE	AC, BA, CH, CY, PL, PR (al, de, ga), VE	Australia	Longford et al. (2007)

Delisea pulchra	CLO, DGGE	BA, PL, PR (al, ga)	Australia	Fernandes (2011)

Gracilaria vermiculophylla	CLO, DGGE	AC, CY, DT, PL, PR (al, be, de)	Germany	Lachnit et al. (2011)

Osmundaria volubilis	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Phyllophora crispa	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Porphyra yezoensis	CLO	BA, LE, PR (al, be, ga)	Japan	Namba et al. (2010)

3 spp. macroalgae	CLO, TRFLP	BA, CY, PL, PR (al, ga), VE	Chile	Hengst et al. (2010)

12 spp. macroalgae	CLO	PL	Portugal	Lage and Bondoso (2011)

Unidentified turf algae	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)


Particle	Loading capacity (%)	Loading efficiency (%)	Size (nm)	Administration route	In vitro/in vivo results	Ref.

NLCs (glyceryl tridecanoate, glyceryl tripalmitate, soy lecithin and Kolliphor HS15, and chitosan)	3	99	50	Oral	High stability in both acidic and neutral environments.In vitro studies performed in THP-1-derived macrophages showed a decrease in inflammation and accumulation of cholesterol.	[27]

NLCs (phosphatidylcholine, Kolliphor HS15, and alpha-tocopherol acetate)	10	96	108	N/A	Increased EGCG stability. Enhanced accumulation inside macrophages and decrease in the production of MCP-1.	[28]

Phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, and phosphatidylinositol	N/A	N/A	30–80	Oral	Enhanced EGCG oral bioavailability in vivo and induction of α-secretase activity in neuronal cells in vitro.	[29]

NLCs (cetyl palmitate/Phospholipon 80, sesame oil, and Tween-80)	2.7–3.6	99	126–167	Topical	Photodegradation of EGCG under UVA radiation.	[30]

SLN (glycerol monostearate, stearic acid, soya lecithin, and Pluronic F68)	N/A	67	157	N/A	Enhanced stability in physiological fluids. Increased induction of cell death in breast cancer cells MDA-MB-231 and prostate cancer cells DU-145.	[31]

Cationic lipid nanocarriers (Softisan® 100, Poloxamer 188, glycerol, Lipoid® S75, and CTAB/DDAB)	N/A	N/A	~150	Ocular	Prolonged release of EGCG in biological medium. Permeation of rabbit cornea and sclera.	[32]


Model	Unstandardized Coefficients B	Unstandardized Coefficients SE	Standardized Coefficient ß	t	p

A. Results of the linear Regression for Variables Predicting PTSD Symptoms

 Constant	−3.28	1.75		−1.88	p = .063

 MACE SUM	0.21	0.06	.29	3.42	p = .001

 Physical Neglect at age 5	2.28	0.80	.24	3.86	p = .005

 Emotional Neglect at age 6	0.60	0.43	.12	1.41	p = .161

 Sexual Abuse at age 12	6.73	1.89	.25	3.56	p = .001

B. Results of the linear Regression for Variables Predicting Symptoms of Shutdown Dissociation

 Constant	3.47	0.73		−1.88	p < .001

 Physical Neglect at age 5	0.70	0.48	.14	1.46	p = .147

 Emotional Neglect at age 4	0.57	0.26	.21	2.17	p = .032

 Parental Non-verbal Emotional Abuse at age 14	0.44	0.26	.16	1.73	p = .086

 Sexual Abuse at age 12	3.02	1.12	.22	2.69	p = .008

C. Results of the linear Regression for Variables Predicting Symptoms of Depression

 Constant	14.82	1.29		11.48	p < .001

 F2 diagnosis	−5.12	0.14	−.34	−4.49	p < .001

 MACE duration	0.01	0.01	.15	1.39	p = .166

 Emotional Neglect at age 9	0.51	0.30	.17	1.67	p = .097

 Sexual Abuse at age 12	2.69	1.37	.16	1.97	p = .051


Characteristic	Rotavirus Diarrhea (n = 71)	Nonrotavirus Diarrhea (n = 149)	P Value

Age, moa	9 (3–27)	10 (2–30)	.335

Male sex	42 (59.2)	78 (52.3)	.422

Prior hospital admission for diarrhea	22 (31.0)	37 (24.8)	.423

Home has a separate room for kitchen	40 (56.3)	88 (59.1)	.813

No. of bedrooms in homea	2 (1–4)	2 (1–4)	.278

No. of people sleeping in homea	7 (1–20)	6 (4–21)	.368

No. of children sleeping in homea	4 (1–8)	3 (1–13)	.459

Family owns a mattress	51 (71.8)	98 (65.8)	.457

Family owns a mobile phone	70 (98.6)	130 (87.2)	.013

Family owns a radio	38 (53.5)	79 (53.0)	1.000

From the Iraqw tribe	37 (52.1)	95 (63.8)	.133

Maternal agea	27 (16–47)	26 (17–41)	.919

Mother completed secondary school	50 (70.4)	87 (58.4)	.116

Protected drinking water source	27 (38.0)	70 (47.0)	.269

Child still breastfeeding	63 (88.7)	119 (79.9)	.151


Author	Age	Symptoms	Site of tumor	Histology	Treatment	Relapse(months)	Treatment of relapse

Our case	56	Urinary symptomsLower abdominal distention	Corpus	IT	Hysterectomy	Yes (3)	BEP × 1

Newsom-Davis et al., 2009 [5]	82	Vaginal bleeding	Corpus	IT	Hysterectomy and bilateral salpingooophorectomy	Yes (6)	EP × 1, ET × 1, TP × 1 + surgery

Gomez-Lobo et al., 2007 [6]	15	Vaginal bleedingPelvic pain	ns	IT, high grade	Lesion excision + chemotherapy	ns	—

Iwanaga et al., 1993 [7]	36	Pelvic painLower abdominal distention	Fundus	IT, grade 3	Hysterectomy + chemotherapy (VAC × 2)	No	—

Ansah-Boateng et al., 1985 [8]	37	Vaginal bleeding	ns	IT, grade 2	Hysterectomy + radiotherapy	No	—


n		1108

Age (yrs)	Median	61.5

	Range	40.2-79

PSA (ng/ml)	Median	6.99

	Range	0.3-20

Pathological Stage	pT2	770 (69.6%)

	pT3	335 (30.4%)

Tumour Grade	Low (GS 6)	153 (13.8%)

	Intermediate (GS 7)	848 (76.5%)

	GS 3+4	583 (68.8%)

	GS 4+3	265 (31.3%)

	High (GS 8-10)	107 (9.7%)

Extraprostatic Extension	Absent	782 (70.6%)

	Present	326 (29.4%)

Seminal Vesicle Invasion	Absent	1042 (94.1%)

	Present	66 (6%)

Recurrence	No	812 (76.8%)

(n=1057)	Yes	245 (23.2%)

Total Tumour Volume (cc)	Median	2.6

	IQR	1.3-4.8

Prostate Volume (cc)	Median	32.2

	IQR	24.2-43.5


Parameter	Unit	Tier within the breeding program

Nucleus	Multiplier	Commercial

Flock breeding ewes	Head	826	7000	180,000

Flock breeding rams	Head	10	70	1800

Ewes mated to terminal sires	%	0	0	20

Ewes/ram	Head	80	100	100

Ewe replacement rate	%	35	35	30

Mixed age ewe lambing ratea	%	210	190	165

Ewe lamb lambing rate	%	100	90	80

Lamb survival	%	79	79	82

Weaning rate	%	166	150	135

Lambs sold as storesb	%	–	–	20


				Cluster

		Professional	Consumer	Organizational	Financial	Regulatory

	Breast	4	9	4	0	0

	Gastrointestinal	2	2	2	0	0

	Genitourinary	2	4	2	0	0

	Gynecological	1	1	1	0	0

	Head and neck	0	2	0	0	0

Diagnosis	Hematologic	1	2	1	0	0

	Lung	0	3	0	0	0

	Melanoma	1	1	1	0	0

	Neuro-oncology	0	0	0	0	0

	Sarcoma	1	0	1	0	0

	Not specified	5	6	5	0	0


	Laparoscopic cholecystectomy(n = 120)	Small-incision cholecystectomy(n = 137)	Statistical analysis

Mortality	0	0

Complications	21	16	p = 0.119

intra-operative	5	3	p = 0.363

postoperative	16	13	p = 0.331

Failed symptom relief	11 (9.2%)	14 (10.2%)	p = 0.777

Operative time (min):

mean (SD)	71.9 (25.8)	60.4 (18.3)	p < 0.001

median (range)	68.5 (26-215)	60.0 (29-105)

Conversion rate	14 (11.7%)	22 (16.1%)	p = 0.312

Operative team:

surgeon-resident	15 (12.5%)	21 (15.3%)	p = 0.515

resident-surgeon	84 (70.0%)	100 (73.0%)	p = 0.596

resident-resident	21 (17.5%)	18 (13.1%)	p = 0.331

Hospital stay*

mean (SD)	2.4 (4.6)	3.1 (12.4)	p = 0.560

median (range)	1 (1 - 36)	2 (1 - 144)

Hospital stay* (without 1 extreme value)mean (SD)	2.1 (3.4)	2.0 (2.4)	p = 0.877

Number of patients with:

1 night stay postoperative	67 (55.8%)	62 (45.3%)	p = 0.091

2 nights stay postoperative	38 (31.7%	56 (40.9%)	p = 0.127


Category from the VIM tool	Phase 1	Phase 3

112 patients	16 patients

Management—investigations, e.g. fields test	88% (99)	100% (16)

Self-management—importance of taking eyedrops	83% (93)	100% (16)

Management—regular monitoring	63% (70)	81% (13)

Management—appointment issues	63% (70)	94% (15)

Treatment—options for eyedrops	60% (67)	100% (16)

Risk—family	55% (62)	100% (16)

Diagnosis	54% (60)	100% (16)

Treatment—side effects	43% (48)	100% (16)

Prognosis—loss of sight	24% (27)	100% (16)

Driving	16% (18)	94% (15)

Support—help with eyedrops	13% (15)	100% (16)

Prognosis—symptomless	11% (12)	100% (16)

Prognosis—sight can’t be recovered	10% (11)	100% (16)

Support—support groups	10% (11)	94% (15)

Prognosis—when treated most don’t go blind	3% (3)	100% (16)

Registration of loss of sight	2% (2)	6% (1)


Variables	Coefficient	Standard error	p-value

Course year	- 0.542	0.215	0.015

Participation in emergency course	- 0.903	0.437	0.044


Complication	Frequencyn	Percent%

Present	73	44.8

Absent	90	55.2

Total	163	100.0


Warm-up 1.47 min	Front leaning stance	L stance

Begin with Postural alignment.Shoulders relaxed and in alignment with hips and feet and all facing forward. When standing, feet start shoulder width apart. Repeat each 4 times.	Step forward one stride length, toes first and facing forward as knee bends. Maintain feet shoulders width apart. Opposite foot, toes slightly turned out (30°) and leg straight. Shift weight to back foot. Bend back knee and straighten front knee when shifting weight to back foot. Both feet remain flat on floor at all times. Connect breath and arms with leg movements (as weight shifts forward, raise arms and take in a deep breath, as shifting back, exhale).	Step back with one foot, making an L with feet (creating a 90° angle). Feet should be a comfortable distance apart and the heel of the back foot should land in line with front foot. Shift weight to back foot and front foot should be settled on heel with toes pointing up in the air. Most of weight on the back foot with knee bent and front knee is straight. Shift weight from back to front foot and bend front knee as back knee straightens. Connect breath and arms with leg movements (as weight shifts forward, raise arms and take in a deep breath, as shifting back, exhale).

Sign Gestures 8.13 min	Description	Integration of Breath

Healthy, Happy, Holy Practiced from standing position, incorporating the front leaning stance	Healthy: Bring hands to chest with palms open. Extend arms forward in a powerful manner with hands clenched into fist as muscles in forearm and upper arm tighten, assuming the boxers posture. Follow timing of music.	Breath:Breathe in as hands placed on chest. Breathe out as arms extended.

Happy: Rolling your hands upward and outward, starting low in your abdomen. This rolling motion is continuous.	Breath: Breathe in as hands move in a continuous motion rolling outward. Breathe out with continuous motion.

Holy: The right index and middle finger (the H sign) glide across the palm of your left hand extending upward and out on an angle.	Breath: Breathe in as the right fingers are placed on the palm of left hand. Breathe out as fingers brush across palm and extend upward and outward.

Check blood pressure and heart rate at 0, 5, and 10 min. (Record heart rate every minute, and up to 10 min following cessation of movement.)


Groups	Treatment groups	Description

Group I	Normal control	Received only diet and water

Group II	Vehicle control	Received water and treated with SRBC

Group III	Positive control	Received Ginseng extract 200 mg/kg

Group IV	Low dosage treatment	Received 125 mg/kg of D. morbifera

Group V	Intermediate dosage treatment	Received 250 mg/kg of D. morbifera

Group VI	High dosage treatment	Received 500 mg/kg of D. morbifera


Branch	Leading toa	#Sets	#Genes in Sets	# Significant Sets

Before Pruning	Without Top Scoring Gene	After Pruning

1	Homininae	African Apes(Hu, Ch, Go)	1,415	7,600	8	6	2

2	Hominidae	Great Apes(Hu, Ch, Go, Or)	1,424	7,849	34	32	7

3	Hominoidae	Apes(Hu, Ch, Go, Gi)	1,441	8,016	43	42	6

4	Catarrhini	Apes & Old World Monkeys (Hu, Ch, Go, Gi, Ma)	1,441	8,058	95	93	9


Gene ID	Annotation	FPKM Ctrl	FPKM -N	Log2 FC

GRMZM2G326707	Inorganic phosphate transmembrane transporter, PHT1;4	73.0	305.5	2.07

GRMZM2G154090	Inorganic phosphate transmembrane transporter, PHT1;4	6.7	695.6	6.69

GRMZM2G112377	Inorganic phosphate transmembrane transporter, PHT1;4	1.4	271.3	7.64

GRMZM2G069542	Phosphoenolpyruvate carboxylase	92.7	154.5	0.74

GRMZM2G074122	Phosphoenolpyruvate carboxylase	42.7	73.6	0.79

GRMZM2G110714	Phosphoenolpyruvate carboxylase	3.2	22.9	2.83

GRMZM2G008507	Sucrose-phosphate synthase	1.2	77.9	6.02

GRMZM2G047995	Lipase class 3 family protein	4.0	87.0	4.45

GRMZM2G169562	Lipase class 3 family protein	2.9	27.3	3.23

GRMZM5G829946	Senescence-related gene 3, glycerophosphodiester phosphodiesterase	0.3	159.3	8.92

GRMZM2G064962	Glycerophosphoryl diester phosphodiester family protein	19.2	108.0	2.49

GRMZM2G315848	Protein nucleotide pyrophosphatase/phosphodiesterase	6.7	65.8	3.29

GRMZM2G477503	Sulfoquinovosyldiacylglycerol 2	6.5	348.0	5.75

GRMZM2G141320	1,2-diacylglycerol 3-beta-galactosyltransferase/UDP-galactosyltransferase	0	159.8	–

GRMZM2G152447	Acid phosphatase/protein serine/threonine phosphatase	1.0	318.8	8.34

GRMZM2G138756	Acid phosphatase/protein serine/threonine phosphatase	0.1	17.7	8.00

GRMZM5G836174	Phosphatase	0.5	1991.8	11.83

GRMZM2G015908	Phosphatase	3.9	309.9	6.30

GRMZM2G021106	Phosphatase	0.4	48.1	6.81

GRMZM2G171423	SPX domain gene 2	1.0	84.6	6.46

GRMZM5G805389	SPX domain gene 3	3.3	1246.0	8.57

GRMZM2G065989	SPX domain gene 3	2.5	1008.0	8.65

GRMZM5G828488	SPX domain gene 3	0.5	399.5	9.65


	Metformin	Pioglitazone	Empagliflozin	Anticipated effect?

Cardiovascular death	↓	↔	↓↓	↓↓↓

All-cause death	↓	↔	↓↓	↓↓↓

Myocardial infarction	↓	↓	↔	↓↓

Stroke	↓	↓	↔	↓↓

Peripheral arterial disease	↓	↔	↔	↓

Fluid retention	↔	↑	↓	↔

Heart failure	↔	↑	↓	↔

Weight	↓	↑	↓	↓

Blood pressure	↔	↓	↓	↓↓

HbA1c	↓	↓	↓	↓↓↓

LDL-cholesterol	↓	↔	↑	↔

HDL-cholesterol	↔	↑	↑	↑↑

Albuminuria	↔	↓	↓	↓↓

Insulin sensitivity	↑	↑↑	↑	↑↑↑↑


Year	Confirmed positive	Donor population	Prevalence by gender	Total prevalence

1st year	Male	124	80253	0.15%	0.18%

Female	36	6524	0.55%

2nd year	Male	133	81841	0.16%	0.19%

Female	34	6044	0.56%

Total		327	174662		0.18%


Variable	Subgroups	Number of respondents	Percentages

Age (years)	<20	33	11.3

20–25	221	75.4

>25	39	13.3

Age of menarche	<13	83	28.3

13–15	161	54.0

> 15	49	16.7

Gynecological age (years)	< 5	14	4.8

5–10	214	73.0

> 10	65	22.2

Religious affiliationa	Christianity	208	71.0

Islam	79	27.0

Type of accommodation at menarchea	Single room	46	15.7

Chamber and hall	55	18.8

Several rooms in a compound house	52	17.7

Self-contained apartment	126	43.0

Mansion	10	3.4

Area of residence during vacationa	Urban area	181	61.8

Sub-urban	88	30.0

Rural	21	7.2


	Dyad 1	Dyad 2	Dyad 3	Dyad 4	Dyad 5

Mother age	43	31	52	45	48

Youth age	13	13	13	13	13

Youth grade	8	8	8	8	8

Youth gender	Girl	Girl	Girl	Boy	Boy

Mother income	$40–49K	$10–19K	$50–74K	$75–99K	$50–74K

Mother education level	Some college	Some college	College graduate	College graduate	College graduate

Race	White	African American	White	White	White


	Number of responses	%	Overall(N Trusts with at least one response/Total N Trusts in regionb)	Diabetes(N Trusts with at least one response)	Cardiac(N Trusts at least one response)

ENGLAND

London	27	15.2	15/22	13	13

South West	23	12.9	12/16	10	8

South Central	10	5.6	5/9	5	4

South East Coast	8	4.5	6/11	6	2

East England	16	9.0	11/17	9	5

Yorkshire & Humber	15	8.4	9/13	8	8

West Midlands	21	11.8	13/15	10	13

East Midlands	8	4.5	5/8	3	5

North East	16	9.0	6/8	4	6

North West	17	9.6	10/20	8	8

Total number in England	161	90.5	92/139	76	72

SCOTLAND	12	6.7	12 responses covering ≥7/14 health boards (2 responses only identified as “Scotland”)	6	6

WALES	3	1.7	3 responses covering 3 of the 7 local health boards.	2	3

NORTHERN IRELAND	2	1.1	2 responses covering 2 of the 5 health and social care Trusts	2	2

Total	178a	100.0


Primer name	Sequence

Notch-1

 Forward	CACTGTGGGCGGGTCC

 Reverse	GTTGTATTGGTTCGGCACCAT

Hes1

 Forward	AGCCAACTGAAAACACCTGATT

 Reverse	GGAGTTTATGATTAGCAGTGG

Dll4

 Forward	GGTGACCTGGCGAACAGACGAGCAAAAT

 Reverse	GGTGACCTGGCGAACAGACGAGCAAAAT

GAPDH

 Forward	GGCATCCTGGGCTACACT

 Reverse	CCACCACCCTGTTGCTGT


Features used	Attribute type

Gene Neighborhood score, obtained from STRING	Real valued, ranges from 0-999

Gene Fusion score, obtained from STRING	Real valued, ranges from 0-999

Gene Co-occurrence score, obtained from STRING	Real valued, ranges from 0-999

Gene Co-expression score, obtained from STRING	Real valued, ranges from 0-999

GO Cellular component based feature	Real valued, ranges from 0-0.5

GO: Molecular function	Real valued, ranges from 0-0.5

GO: Biological process	Real valued, ranges from 0-0.5


	Number of cases	Gender (%)	Age median (Range)	PDAC stage (%)

Cohort 1 (Exploratory phase)

Healthy	n = 16	M (62.5)F (37.5)	59 (54–65)	Stage IA (16)Stage IIA (24)Stage IIB (56)ND (4)

PDAC	n = 25	M (40)F (60)	50 (47–82)

Cohort 2 (Confirmatory phase)

Healthy	n = 131	M (49.6)F (50.4)	55 (44–66)	Stage IA (1.5)Stage IB (0.8)Stage IIA (16.8)Stage IIB (66.4)Stage III (0.8)Stage IV (2.3)ND (11.4)

Chronic pancreatitis	n = 30	M (73.3)F (26.7)	53 (34–79)

PDAC	n = 131	M (49.6)F (50.4)	70 (38–88)


Variables	Evaluation instruments	Quality of instruments	Time application instruments

Demographic & obstetric data	Included in antenatal interview	 	Antenatal

Antenatal risk of PPD	Interview (Riguetti-Veltema & et. al, [14])	Sensitivity = 84,5%, Specificity = 73%	Antenatal

Symptoms of depression	EPDS*Edinburgh Postnatal Depression Scale (Cox & et. al, [51])	Sensitivity = 86%, Specificity = 78%	Antenatal and postnatal

Relationship with partner	DASS*Dyadic Adjustement Scale (Spanier, [52])	Fidelity: Cronbach Alpha = 0.96	Antenatal and postnatal

Social support	FSSQ*Functional Social Support Questionnaire (Broadhead, [53])	Fidelity: Cronbach Alpha = 0.90	Antenatal and postnatal

Stress	Stress events* (Holmes & Rahe, [54])	 	Antenatal and postnatal

Birth outcomes	Hospital clinical data and post-partum questionnaire*	 	Postnatal


Characteristic	Frequency	Percentage

Sex

 Male	372	62.0

 Female	228	38.0

Age category

 1 (15–35)	287	47.8

 2 (36–55)	202	33.7

 3 (≥56)	111	18.5

HIV status

 Positive	162	27.0

 Negative	438	73.0

Mycobacterial testing results

 ZN smear positive	34	12.1

 LED-FM smear positive	16	5.0

 Xpert positive	82	13.7

 Culture (MGIT and/or LJ) positive	96	16.0


BSI scale	UK outpatient mean/SD	Pretreatment score	Posttreatment score

PAR	M = 1.54/SD = 1.08∗	2.20	1.50

ANX	M = 1.87/SD = 1.03∗	2.50	1.60


Title	No of species	Authors	Reference

Sporadic study in India	20	Gosh A K, Maiti P K	[44]

Bhil of Rajasthan	17	Sharma S K	[43]

Bhil, Gamit, Kokna etc. of Maharastra	15	Patil S H	[42]

Chhattisgarh	10	Oudhia P	[41]

Chhattisgarh	7	Oudhia P	[40]

Kachch (Gujrat)	34	Gupta Leena et al.	[39]

Irular, Kurimba of Tamilnadu	26	Solvan A et al.	[38]

Kanikar, Paliyar of Taminadu	11	Ranjit Singh ASA	[37]

Mogya, Meena, Bawaria of Rajasthan	15	Mahawar, Jaroli	[33]

Saharia of Rajasthan	15	Mahawar, Jaroli	[36]

Monpas	11	Solanki GS and Chutia P	[11]

Mizoram	56	Lalramnghinglova	[12]

Chakhesang of Nagaland	23	Kakati and Doulo	[16]

Naga tribe of Nagaland	26	Jamir N S et al.	[14]

Dibrugarh (Assam)	4	Dilip Kalita	[15]

Ao tribe of Nagaland	25	Kakati L N et al.	[17]

Nyishi & Galo Tribe of Arunachal Pradesh	36	Chakravorty et al.	[13]

Biate Tribe, Dima Hasao, Assam	34	Present Study


Material	Total thermal conductivity (W/m-K)	LA (%)	TA (%)	ZA (%)	Optical (%)

Black phosphorene (zigzag)	110	32	22	31	15

Black phosphorene (armchair)	36	28	33	12	27

Blue phosphorene	78	26	27	44	3

MoS229	108	28	24	39	9

Graphene30	3600	8	15	76	1


Parameters	NGT	Pre-diabetes	p value

	(n = 24)	(n = 26)

Anthropometric measures

Age (years)	36 ± 2	39 ± 2	0.232

Weight (Kg)	69 ± 2	77 ± 3*	0.026

Body Mass Index (kg/m2)	24.0 ± 0.6	26.5 ± 0.6*	0.005

Waist Circumference (cm)	90.3 ± 1.7	98.3 ± 3.1*	0.032

Waist - Hip Ratio	0.96 ± 0.01	0.98 ± 0.01	0.070

Systolic Blood Pressure (mmHg)	119.0 ± 1.8	122.8 ± 2.6	0.240

Diastolic Blood Pressure (mmHg)	76.3 ± 1.6	76.6 ± 1.9	0.992

Biochemical parameters

OGTT

Fasting plasma glucose (mmol/l)	5.0 ± 0.1	5.7 ± 0.1**	0.0001

2Hr Post plasma glucose (mmol/l)	5.6 ± 0.2	8.1 ± 0.3**	0.0001

Glycated Hemoglobin [HbA1c] (%)	5.4 ± 0.1	5.8 ± 0.1*	0.0013

Fasting Insulin (pmol/l)	49.8 ± 5	95.1 ± 10**	0.0002

2Hr post Insulin (pmol/l)	325.8 ± 49	780.0 ± 75**	0.0001

HOMA-IR	1.9 ± 0.2	4.0 ± 0.4**	0.0001

Lipid profile

Total Cholesterol (mmol/l)	4.6 ± 0.2	4.9 ± 0.2	0.376

Serum Triglycerides (mmol/l)	1.51 ± 0.2	1.9 ± 0.2	0.166

HDL Cholesterol (mmol/l)	1.0 ± 0.04	0.9 ± 0.04	0.459

LDL Cholesterol (mmol/l)	2.9 ± 0.1	3.0 ± 0.2	0.632

VLDL Cholesterol (mmol/l)	0.7 ± 0.1	0.9 ± 0.1	0.163

Others

Serum Creatinine (μmol/l)	79.6 ± 1.8	106.9 ± 27.1	0.364

Hs-CRP (mg/l)	2.5 ± 0.5	3.1 ± 0.5	0.341

Microalbuminuria (μg/mg)	5.2 ± 0.8	7.6 ± 1.5	0.344


	Case 1	Case 2	Case 3

Age, years	59	41	46

Sex	Female	Female	Female

Initial stage	1A	ND	2A

Histology	IDC	IDC	ILC

Histological grade	2	2	1

Nuclear grade	1	2	1

Estrogen receptor (AS)	Negative (0)	Positive (8)	Positive (8)

Progesterone receptor (AS)	Negative (0)	Positive (8)	Positive (8)

HER2 status (IHC score)	Negative (0)	Negative (0)	Negative (1+)

PIK3CA hotspot mutation	H1047R	Negative	H1047R

TERT hotspot mutation	C250T	C228T	C228T

Relapse-free survival, months	83	226	270

Overall survival, months	100	446	300

Status	Alive	Alive	Alive


Code	Value	% Age	Description

J	165	2.51	Translation, ribosomal structure and biogenesis

A	0	0.00	RNA processing and modification

K	131	1.99	Transcription

L	620	9.44	Replication, recombination and repair

B	1	0.02	Chromatin structure and dynamics

D	47	0.72	Cell cycle control, Cell division, chromosome partitioning

V	67	1.02	Defense mechanisms

T	138	2.10	Signal transduction mechanisms

M	203	3.09	Cell wall/membrane biogenesis

N	30	0.46	Cell motility

U	52	0.79	Intracellular trafficking and secretion

O	152	2.31	Posttranslational modification, protein turnover, chaperones

C	185	2.82	Energy production and conversion

G	131	1.99	Carbohydrate transport and metabolism

E	215	3.27	Amino acid transport and metabolism

F	62	0.94	Nucleotide transport and metabolism

H	146	2.22	Coenzyme transport and metabolism

I	65	0.99	Lipid transport and metabolism

P	188	2.86	Inorganic ion transport and metabolism

Q	126	1.92	Secondary metabolites biosynthesis, transport and catabolism

R	535	8.14	General function prediction only

S	483	7.35	Function unknown

-	2,826	43.02	Not in COGs


SSRs	Probes used in study	References

		Mitotic chromosomes	Polytene chromosomes

A	A20		(21, 40)

C	C20		(40)

AC; AG	(AC)10; (AG)10	(27)	(27, 40)

AAC; AAG; AAT, AAC; AGC; ACT; AGC; AGG; ATC; CCG	(AAC)5; (AAG)5; (AAT)5; (ACC)5; (ACG)5; (ACT)5; (AGC)5; (AGG)5; (ATC)5; (CCG)5

GACA	(GACA)5		(21)

GATA	(GATA)5	(31)	(21)

AAGAC; AAGAG; AATAC; AATAT	(AAGAC)3; (AAGAG)3; (AATAC)3; (AATAT)3	(10)

AACAC	(AACAC)3;	(11)	(11)


		N = 14 (%)

Clinical characteristics

Age (SAH), years (mean, SD)		46.1 ± 12Range: 20–63

Age (healthy controls), years (mean, SD)		47.1 ± 12Range: 20–64

Gender (SAH), female		8 (57)

Gender (healthy controls), female		8 (57)

Admission H&H grade	1	9 (64)

2	4 (29)

3	1 (7)

Loss of consciousness		0 (0)

Admission APACHE II score		4 (2–5)

Admission radiological characteristics

mFisher scale	0	1 (7)

1	1 (7)

2	1 (7)

3	6 (43)

4	5 (36)

SAH sum score		13Range: 10–15

IVH sum score		0 (0–2)

Aneurysm location AcomA = anterior communicating artery		5 (36)

No aneurysm detected		9 (64)

Aneurysm size above 10 mm		0 (0)

Generalized cerebral edema		0 (0)

Intracerebral hematoma		0 (0)

Surgical procedures

Hydrocephalus requiring EVD/Shunt		0 (0)

Coiling		5 (36)

Clipping		0 (0)

No aneurysm		9 (64)

Hemicraniectomy		0 (0)

Complications

Pneumonia		0 (0)

Delayed cerebral infarction		0 (0)

Anemia requiring transfusion		0 (0)

Aneurysm rebleeding		0 (0)

Hyperosmolar therapy		0 (0)

Outcome characteristics

Length of hospital stay, days		19.5Range: 17–21

Discharge mRS	0	9 (64)

1	5 (36)

3‐month mRS	0	9 (64)

1	5 (36)

12‐months mRS	0	11 (79)

1	3 (21)


Location	Tissue	Date of collection	Time period reflected	N	N males	N females

Newfoundland	Claws	April 2016	Winter	24	8	16

Whole blood	December 2013 to January 2014	Winter	35	30	5

Nuuk, Greenland	Claws	April 2014	Winter	33	6	29

Whole blood	April 2014	Late winter	34	6	29

East Bay Island	Claws	June to July 2014	Winter	109	0	109

Red blood cells	June to July 2014	Spring migration	108	0	108

Claws	June to July 2015	Winter	115	43	72

Red blood cells	June to July 2015	Spring migration	125	51	74


Suggestions from COECSA partners	Suggestions from United Kingdom partners

Program planning and design• There is need for continuous dialog and joint planning• COECSA to drive the process by demonstrating both demand and ownership• More opportunities for visits to the United Kingdom to “see how things are done”• LINK to facilitate setting up of more VISION 2020 twinning links in the region• LINK to provide more scope for interaction between the institutions in the ECSA region• Expand the scope of collaboration to include research, subspecialty programs, mentoring and instrumentsProgram implementation• Build capacity of editors of the scientific journal• Involve middle-level eye care cadres in the LINK• Training of examiners should be more intensive than just 1 day before the exams, “perhaps even organized in modules”• Make the partnership equal and mutual• Strengthen leadership of the COECSA and the LINKEvaluation• Gather evidence to demonstrate impact of the LINK• Strengthen monitoring and evaluation, and source funding for it	Program planning and design• Build on the successes of the partnership in future planningProgram implementation• COECSA needs to build develop staff to take lead in all the activities• Ensure the right people are on board for LINK activities• Encourage continuity for lead roles or smooth handover/transition when new persons take up roles• Aim to make each activity effective and evaluate effectiveness• Ensure United Kingdom facilitators have clarity on their roles• Improve frequency and regularity of communicationEvaluation• COECSA to strengthen reporting on LINK activities• Constantly evaluate if expectations of COECSA are being met


	STAV-AB xenograft	STAV-FCS xenograft	Localization

MESOTHELIAL AND EPITHELIAL MARKERS

Calretinin	++	++	Cytoplasm and nucleus

EMA	+	+(+)	Cell membrane

E-cadherin	+ (Focal)	+	Cell membrane

CK-HMW	++	++	Cytoplasm

Cytokeratin 7	+	++	Cytoplasm

Cytokeratin 8	−	−	Cytoplasm

Cam 5.2	+++	++	Cell membrane and cytoplasm

Syndecan-1	+	+	Cell membrane

MNF-116	+++	+++	Cell membrane and cytoplasm

DIFFERENTIATION-RELATED MARKERS

TrxR1	++	+++	Cytoplasm and nucleus

Integrin α5	+	+	Cytoplasm

HSP-47	+++	+++	Cell membrane and cytoplasm

Annexin-II	++	++	Cell membrane

MESENCHYMAL MARKERS

Vimentin	++	++	Cytoplasm

SM actin	+(+)	+	Cytoplasm

Syndecan-2	++	++	Cytoplasm

PROLIFERATION MARKER

Mib-1	>80%	40%	Nucleus


Antibody	Supplier	Western dilution

β-Actin	Sigma Aldrich	1 in 3000

CDK6	Santa Cruz	1 in 200

γH2AX (Ser139)	Cell Signaling	1 in 1000

Lamin a/c	Santa Cruz	1 in 500

MEK2	BD Biosciences	1 in 3000

PP1α	Bethyl Laboratory	1 in 1000

PP1β	Bethyl Laboratory	1 in 1000

PP1γ	Santa Cruz	1 in 200

p53	Oncogene	1 in 500

pATM (Ser1981)	Epitomics	1 in 500

p-p53 (Ser15)	Cell Signaling	1 in 500

Rad21 (SCC1)	abcam	1 in 1000

Rb	Santa Cruz	1 in 200

p73	Santa Cruz	1 in 100

p63	abcam	1 in 1000

p63(TA)	bioLegend	1 in 1000


Tocopherol	Cell type/Cancer model	Result	References

α-Tocopherol	Human retinal pigment epithelial cells (ARPE-19)	↑ Nrf2 protein levels, ↑ glutamate cysteine ligase, NQO1, HO-1, GST, SOD	[90]

γ-TmT	Prostate carcinogenesis in TRAMP male mice	↑ Nrf2 protein levels, ↑ GSTm1, UGT1A1, HO-1, catalase, SOD, glutathione peroxidase,	[43]

γ-TmT	Estrogen-induced mammary hyperplasia in female ACI rats	↑ Nrf2 protein levels	[92]


 	CBHI (26)	Non-CBHI (114)	t-test

Population density (per km2)	184.62	46.42	-2.571*

Poverty rate (%)	29.6	40.1	3.386**

Literacy rate (%)	79.00	64.2	-4.061**

% of labor non-agriculture	33.38	12.09	-5.868**

% HHs with electricity	73.7	41.87	-5.948**

Avg time to nearest health center (mins)	57.65	161	4.5322**

% pop Lao-tai (vs. ethnic minority)	56.09	26.93	-3.741**

% pop Buddhist	79.48	53.29	-3.71**


Characteristic	Amiodarone n=20	Metaprolol n=30	P value

AF%age	20%	26.7%	NS

Time of Development of AF	62.15+ 18	48.4+ 10.2	NS

Duration of AF	12.04+ 10.2	18.8+ 10.4	NS

Maximum Ventricular rate during AF	118.+ 30.4	148+ 22.2	NS

AF on discharge	1	3	NS

Length of hospital stay	12.7+ 4.5	13.2+ 5.2	NS

Cost of Care	1.17+ 0.12	1.18+0.10	NS


Characteristics	Number of patients (%)

Sex

Male	42 (98)

Female	1 (2)

Age (years)

Range	39–80

Median	66

Stage

T1	1 (2)

T2	16 (37)

T3	9 (21)

T4	17 (40)

N

Yes	3 (7)

No	39 (91)

NA	1 (2)

M

Yes	6 (14)

No	36 (84)

NA	1 (2)

Histological type

Papillary	3 (7)

Colonic	25 (58.1)

Solid	5 (11.6)

Mucinous	10 (23.3)

Wood dust exposure

Yes	26 (60)

No	9 (21)

NA	8 (19)

Recurrence

Yes	24 (56)

No	17 (40)

NA	2 (4)

Outcome

Alive	16 (37)

Died of disease	16 (37)

Died of other causes	9 (21)

NA	2 (5)


Before the phlebotomy training May 2014	After the phlebotomy training July 2014

CHC/CDC	Blood registrations	Blood rejections n (%)	Blood registrations	Blood rejections n (%)	p

A	7557	60 (0.79)	10 218	79 (0.77)	0.876

B	3973	45 (1.13)	4114	48 (1.17)	0.886

C	2321	38 (1.64)	2279	37 (1.62)	0.971

D	589	8 (1.36)	630	7 (1.11)	0.696


	K	AIC	ΔAICc	wi

All species

 Distance to road	2	2401.35	0	0.78

 Constant survival	1	2405.17	3.82	0.11

 Distance to edge	2	2406.59	5.24	0.06

 Distance to power lines	2	2407.04	5.69	0.05

 Macrohabitat type	5	2411.51	10.16	0.00

 Species	16	2424.29	25.86	0.00

BLGR

 Distance to edge	2	201.684	0	0.48

 Constant survival	1	207.16	1.19	0.26

 Distance to power lines	2	208.28	2.59	0.13

 Distance to road	2	209.26	3.15	0.10

 Macrohabitat type	5	212.60	6.48	0.02

BRTH

 Constant survival	1	273.10	0	0.37

 Distance to edge	2	274.11	1.01	0.22

 Distance to road	2	274.90	1.80	0.15

 Macrohabitat type	4	175.12	2.02	0.13

 Distance to power lines	2	275.229	2.13	0.13

INBU

 Distance to power lines	2	188.55	0	0.83

 Constant survival	1	193.48	4.93	0.07

 Macrohabitat type	5	194.29	5.74	0.05

 Distance to edge	2	195.51	6.96	0.03

 Distance to road	2	195.71	7.16	0.02

NOCA

 Constant survival	1	1225.21	0	0.44

 Distance to power lines	2	1226.68	1.47	0.21

 Distance to road	2	1227.02	1.81	0.18

 Distance to edge	2	1227.24	2.03	0.16

 Macrohabitat type	5	1232.03	6.81	0.01

WEVI

 Constant survival	1	76.03	0	0.59

 Distance to power lines	2	78.33	2.30	0.19

 Distance to edge	2	79.38	3.34	0.11

 Distance to road	2	79.39	3.36	0.11

 Macrohabitat type	4	89.69	13.65	0.00


	Gene name	Gene Accession number	Score (d)	Log2 expression ratio

Genes mainly expressed in skeletal muscle	Nebulette (Actin-binding Z-disk protein)	NM_006393	42.93	3.81

	Troponin I, fast skeletal muscle (Troponin I, fast-twitch isoform)	NM_003282	34.39	2.60

	Huntingtin interacting protein 1 (HIP-I)	NM_005338	33.55	2.59

	Myosin light chain 2a	NM_021223	32.80	3.26

	Troponin C, skeletal muscle	NM_003279	32.21	2.45

	Myosin light chain 2	NM_013292	29.25	3.06

	Myosin heavy chain, skeletal muscle, perinatal	NM_002472	28.14	2.80

	Troponin T, fast skeletal muscle isoforms	NM_006757	26.04	2.71

	Myosin heavy chain, cardiac muscle beta isoform	NM_000257	24.94	3.12

	Actin, alpha skeletal muscle (Alpha-actin 1)	NM_001100	24.21	3.50

	Troponin C, slow	NM_003280	21.31	2.54

	Nebulin	NM_004543	20.17	2.78

	Smoothelin	NM_134269	19.50	1.32

	Tropomyosin 1 alpha chain (Alpha-tropomyosin)	NM_000366	18.92	1.99

	Myotilin	NM_006790	18.07	1.56

Genes mainly expressed in MCF-7 cells	Actin, cytoplasmic 2 (Gamma-actin)	NM_001614	-30.24	-2.58

	Elongation factor 1-beta (EF-1-beta)	NM_001959	-22.14	-1.26

	Actin binding protein anillin,	NM_018685	-20.12	-1.13

	Keratin, type I cytoskeletal 18	NM_000224	-18.78	-2.83

	Ankyrin 3 (ANK-3) (Ankyrin G)	NM_020987	-16.43	-2.17

	Gamma-parvin	NM_022141	-16.30	-1.03

	Spectrin beta chain, brain 2 (Spectrin, non-erythroid beta chain 2) (Beta-III spectrin)	NM_006946	-16.28	-0.84

	Coronin 1B (Coronin 2)	NM_020441	-15.97	-0.84

	Beta-centractin (Actin-related protein 1B) (ARP1B)	NM_005735	-15.79	-1.40

	NB thymosin beta	NM_021992	-14.92	-1.42

	Coronin 2A (WD-repeat protein 2) (IR10)	NM_052820	-14.39	-1.24

	ARP2/3 complex 16 kDa subunit (P16-ARC) (Actin-related protein 2/3 complex subunit 5)	NM_005717	-13.74	-1.06

	Tight junction protein ZO-1 (Zonula occludens 1 protein) (Zona occludens 1 protein) (Tight junction protein 1)	NM_003257	-13.70	-1.28

	Transcription factor 7 (T-cell-specific transcription factor 1) (TCF- 1) (T-cell factor 1)	NM_003202	-13.60	-0.67

	Catenin delta-1 (p120 catenin) (p120(ctn)) (Cadherin-associated Src substrate) (CAS) (p120(cas))	NM_001331	-13.60	-0.77


Gene IDa	Primers (5′-3′)	Accession No.	Amplicon length

Act- β	Forward: CGGCATCGAGGACAGGATReverse: CATCGTACTCCTGCTTGCTGAT	NM_173979.3	169

GAPDH	Forward: CCTGCCCGTTCGACAGATAReverse: GGCGACGATGTCCACTTTG	NM_001034034.1	150

FAU	Forward: CCGCATGCTTGGAGGTAAAGReverse: CACAACATTGACAAAGCGCC	NM_174731.3	154

RPS9	Forward: CCGCATGCTTGGAGGTAAAGReverse: CACAACATTGACAAAGCGCC	NM_001101152.2	188

HPRT1	Forward:GGATTACATCAAAGCACTGAACAReverse: CATTGTCTTCCCAGTGTCAATT	NM_001034035	194


Item	Descriptions

Number of stations	12

Date span 	1–30 May 2015; 1–30 July 2016

Signal selection	GPS: L1/L2/L5; GLONASS: L1/L2; BeiDou: B1/B2/B3; Galileo: E1/E5a/E5b

Sampling interval	30 s

Elevation cut off	10°

Time system	GPS time

Tropospheric delay	Dry component: corrected with GPT model [26], wet component: estimated as random-walk process, GMF mapping function applied.

First order ionospheric delay	Single-frequency SPP:

GPS/GLONASS: Klobuchar model

BDS: Klobuchar model [27]

Galileo: The NeQuick model [28]

Dual-frequency: First order eliminated by ionosphere-free combination

Relativistic effect	IERS2010 [29]

Sagnac effect	IERS2010 [29]

Phase wind-up effect	Corrected [30]

Satellite PCO and PCV	GPS and GLONASS: Fixed to igs08_1861.atx values;

Tide displacement	IERS2010 [29]

Station reference coordinates	IGS SINEX solutions or daily GPS-only PPP solutions


Ethnic group	α-globin genotypes	Total

- -α3.7/αα	- -α4.2/αα	- -SEA/αα

Malay (n = 315)	32	0	1	33

Chinese (n = 73)	2	1	1	4

Indian (n = 12)	0	0	0	0

Total (n = 400)	34	1	2	37


Species Name	LC50/EC50 (95% Confidence Interval Limit)	Study

Oreochromis niloticus	3760 mg∙L−1 (2990–4010)	Omoregie et al. (2009) [39]

Chironomus yoshimatsui	1520 mg∙L−1	Kegley et al. (2014) [40]

Viviparus bengalensis	2280 mg∙L−1	Kegley et al. (2014) [40]

Radix luteola	3000 mg∙L−1	USEPA, (2015) [41]


	2010 auditn = 82	2011 re-auditn = 140

Patients who had at least one neuroimaging procedure (through MAS or previous), n (%)	56 (68)	106 (76)

Neuroimaging requested through MAS, n (%)	48 (59)	88 (63)

Previous neuroimaging, n (%)	8 (9)	18 (13)

Patients who declined assessment/scan, n (%)	13 (16)	29 (21)

Patients with documented reasons for not having neuroimaging (unable to tolerate scan, moved out of area, died), n (%)	0 (0)	4 (3)

Patients with no reason documented for not having neuroimaging, n (%)	13 (16)	1 (1)

Of the patients who did not have any neuroimaging, proportion with no reason documented, n/N (%)	13/26 (50)	1/34 (3)

Type of neuroimaging performed (through MAS and previous), n/N (%)

CT scan	49/56 (88)	92/106 (87)

MRI scan	5/56 (9)	14/106 (13)

Other (FDG-PET/CT, HMPAO-SPECT)	2/56 (4)	0/106 (0)

Coronal imaging on CT scans requested through MAS, n/N (%)	Data not available	45/78 (58)

Length of time between scan requests and scan appointments, days

Range	6-42	11-71

Mean	22	30

Range across different sectors of patients who had a neuroimaging procedure, %	33-100	58-84


Parameter	Definition

N	Number of individuals in the population

Z	Probability to reproduce by self-fertilization

w	Fitness of an individual

n	Number of TE copies in the genome

si	Effect of insertion i on fitness

μs	Average effect of TE insertions on fitness

σs	Standard deviation of the effect on fitness

Ps > 0	Proportion of TE insertions that improve the fitness

u	Replicative transposition rate

v	Deletion rate

ai	Activity of a copy i (ability to produce the transposition machinery)

m	Mutation rate (toward a less active copy)

σm	Standard deviation of the effect of a mutation on activity


Gene list	N genes	Proportion of genome	SNP heritability (P value)

SNPs	Mb	All samples	Infliximab+Adalimumab

Whole genome	—	1	1	0.18 (0.02)	0.36 (0.005)

Drug metabolism*	215	0.07	0.10	0.05 (0.3)	0.04 (0.09)

Immune-related†	6,001	0.65	0.58	0.07 (0.2)	0.21 (0.01)

TNF/TNFR pathway‡	333	0.11	0.14	0.05 (0.04)	0.02 (0.3)

CD84 coexpression (ImmGen)	200	0.08	0.11	0 (0.5)	0 (0.5)